Respiratory Notes: Respiratory Therapist's Pocket Guide (Davis's Notes)

Copyright © 2008 by F. A. Davis. 00White (F)-FM 4/6/07 11:14 AM Page 3 Copyright © 2008 by F. A. Davis. Respirato...

Author: Gary C. White

553 downloads 3613 Views 5MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form

DOWNLOAD PDF

Copyright © 2008 by F. A. Davis.

00White (F)-FM

4/6/07

11:14 AM

Page 3


Respiratory

Notes Respiratory Therapist’s Pocket Guide

Gary C. White, MEd, RRT, RPFT Purchase additional copies of this book at your health science bookstore or directly from F. A. Davis by shopping online at www.fadavis.com or by calling 800-323-3555 (US) or 800-665-1148 (CAN) A Davis’s Notes Book

F. A. Davis Company • Philadelphia

00White (F)-FM

4/6/07

11:14 AM

Page 4


F. A. Davis Company 1915 Arch Street Philadelphia, PA 19103 www.fadavis.com Copyright © 2008 by F. A. Davis Company Copyright © 2008 by F. A. Davis Company. All rights reserved. This product is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in China by Imago Last digit indicates print number: 10 9 8 7 6 5 4 3 2 1 Acquisitions Editor: Andy McPhee Manager of Content Development: Deborah J. Thorp Developmental Editor: Keith Donnellan Art and Design Manager: Carolyn O’Brien As new scientific information becomes available through basic and clinical research, recommended treatments and drug therapies undergo changes. The author(s) and publisher have done everything possible to make this book accurate, up to date, and in accord with accepted standards at the time of publication. The author(s), editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of the book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised always to check product information (package inserts) for changes and new information regarding dose and contraindications before administering any drug. Caution is especially urged when using new or infrequently ordered drugs. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by F. A. Davis Company for users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the fee of $.10 per copy is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is: 8036-1467/08 0 ⫹ $.10.

00White (F)-FM

4/10/07

6:55 PM

Page 5


Place 2 7/8⫻2 7/8

Sticky Notes

here

For a convenient and refillable note pad

✓ HIPAA Compliant ✓ OSHA Compliant

Waterproof and Reusable Wipe-Free Pages Write directly onto any page of Respiratory Notes with a ballpoint pen. Wipe old entries off with an alcohol pad and reuse.

BASIC

BED ADV ASSESS ASSESS

PROC

CRIT CARE

NEO PEDS

PHARM

TOOLS

00White (F)-FM

4/6/07

11:14 AM

Page 6


Look for our other Davis’s Notes titles RNotes® Nurse’s Clinical Pocket Guide, 2nd edition ISBN-10: 0-8036-1335-0 / ISBN-13: 978-0-8036-1335-5 Coding Notes Medical Insurance Pocket Guide ISBN-10: 0-8036-1536-1 / ISBN-13: 978-0-8036-1536-6 Derm Notes Dermatology Clinical Pocket Guide ISBN-10: 0-8036-1495-0 / ISBN-13: 978-0-8036-1495-6 ECG Notes Interpretation and Management Guide ISBN-10: 0-8036-1347-4 / ISBN-13: 978-0-8036-1347-8 IV Therapy Notes Nurse’s Clinical Pocket Guide ISBN-10: 0-8036-1288-5 / ISBN-13: 978-0-8036-1288-4 LabNotes Guide to Lab and Diagnostic Tests ISBN-10: 0-8036-1265-6 / ISBN-13: 978-0-8036-1265-5 LPN Notes Nurse’s Clinical Pocket Guide ISBN-10: 0-8036-1132-3 / ISBN-13: 978-0-8036-1132-0 MedSurg Notes Nurse’s Clinical Pocket Guide ISBN-10: 0-8036-1115-3 / ISBN-13: 978-0-8036-1115-3 NutriNotes Nutrition & Diet Therapy Pocket Guide ISBN-10: 0-8036-1114-5 / ISBN-13: 978-0-8036-1114-6 MA Notes Medical Assistant’s Pocket Guide ISBN-10: 0-8036-1281-8 / ISBN-13: 978-0-8036-1281-5 OB Peds Women’s Health Notes Nurse’s Clinical Pocket Guide ISBN-10: 0-8036-1466-7 / ISBN-13: 978-0-8036-1466-6 Ortho Notes Clinical Examination Pocket Guide ISBN-10: 0-8036-1350-4 / ISBN-13: 978-0-8036-1350-8 PsychNotes Clinical Pocket Guide ISBN-10: 0-8036-1286-9 / ISBN-13: 978-0-8036-1286-0 Screening Notes Rehabilitation Specialists Pocket Guide ISBN-10: 0-8036-1573-6 /ISBN-13: 978-0-8036-1573-1 Rehab Notes Evaluation and Intervention Pocket Guide ISBN-10: 0-8036-1398-9 /ISBN-13: 978-0-8036-1398-0 IV Med Notes IV Administration Pocket Guide ISBN-10: 0-8036-1446-2 / ISBN-13: 978-0-8036-1466-8 MedNotes: Nurse’s Pharmacology Pocket Guide, 2nd Edition ISBN-10: 0-8036-1531-0 / ISBN-13: 978-0-8036-1531-1 For a complete list of Davis’s Notes and other titles for health care providers, visit www.fadavis.com.


Droplet

Airborne

Contact

Private room. Cohorting is OK if the second patient has the same organism. Private room (negative pressure with 6–12 air changes per hour). Cohorting is OK if the second patient has the same organism. Private room. Cohorting is OK if the second patient has the same organism.

Gloves and Gown

Respiratory Protection

Patient Transport

Always wear gloves and Surgical mask Patient should wear gown. a mask during transport.

Always wear gloves and HEPA mask gown.

During transport the patient should wear a HEPA mask.

Wear gloves for any No mask is patient contact. Wear required. gown if you anticipate contact with patient, soiled equipment, or soiled environmental surfaces.

During transport ensure that any contact transmission by the patient is minimized.

BASICS

Isolation Category Patient Placement

1

Page 1 11:22 AM 4/6/07 01White (F)-01

Isolation Categories

Age Group

Fears/ Anxieties

Verbal Strategies

Senses

Motor Skills

Cognitive Ability

Infants

Speak in a Loud Gross motor Minimal. Anxiety low, soft, noises skills. toward calm voice. may strangers. startle an Fear of infant. separation from parent(s).

Toddlers

Separation from parent(s).

Use concrete Senses are verbal comacute. munication strategies.

Special Considerations

Never leave unattended; always use side rails on cribs. Support head and neck, protecting the airway. Can under- Requires close Begin to stand develop supervision. more than fine motor Don’t leave they can skills. small objects verbalize. that may become a choking hazard.

BASICS

(Text continued on following page)

2


Page 2 11:22 AM 4/6/07 01White (F)-01

Age-Specific Considerations


Fears/ Anxieties Separation, death, disability, injury, pain.

Verbal Strategies

Senses

Motor Skills

Use conSenses crete are verbal acute. strategies.

Good motor skills.

Be more Senses Adoles- Embarrassment, loss of thorough are cent control, loss in explaacute. of consciousnations. ness, changes in appearance/function, separation from peer group.

Good motor skills.

Child

Cognitive Ability


Can underDon’t leave stand more, sharps or explain why other potena child will tially hazarbenefit from dous items at treatment or the bedside. a procedure. Privacy becomes more important. May be Privacy is very capable of important. abstract Encourage thought. verbalization and participation in health-care decisions.


BASICS

Age Group

3

Page 3 11:22 AM 4/6/07 01White (F)-01

Age-Specific Considerations (Continued)

BASICS

Age Group

Fears/ Anxieties

Verbal Strategies

Senses

Motor Skills

Cognitive Ability

Possesses Reflexes Hearing, Be more abstract may be taste, and thorough thought. slower, sight may in explabalance decline. nations. and coorInvolve dination the patient may be in healthdimincare deciished. sions.


Be aware of values effect on patient’s care. Endurance may be diminished. Independence and fostering self-care should be encouraged. Possesses Patient’s skin is Joints are Hearing, Geriatric Loss of control, Be more more fragile. changes in stiffer and abstract taste, thorough thought. Patient may appearance/ less sight in explaDementia have function, (cataracts, mobile. nations. or other dysphasia. separation Balance macular Involve mental Patient should from spouse may be the patient degeneradiminishbe involved in (significant more tion, etc.) in healthment may decisionother), death. care decidiminmay be present. making. ished. decline. sions. Adult

Loss of control, changes in appearance/ function, separation from spouse, death.

4


Page 4 11:22 AM 4/6/07 01White (F)-01

Age-Specific Considerations (Continued)

5

Characteristics

African Americans

Arab Americans

Eye contact

Establish trust and demonstrate respect.

Females may avoid eye contact with males and strangers.

Touching

Generally accept therapeutic touch. Establish trust first.

Is generally acceptable within the same gender, but is not acceptable between genders.

Gender role differences

Responsibility for decision-making varies by educational level and socioeconomic status.

Most decisions are made by men. Care for daily needs is delegated to women.

Religion and spirituality

Belong to Baptist and other Protestant sects; Muslim.

Muslim (generally Sunni branch), also Protestant, Greek Orthodox, or other Christian faiths.

Blood/organ donation

Will refuse blood if a Jehovah’s Witness. Are reluctant to donate blood or organs.

Mutilation of the body (autopsy) or organ donation may be refused. Some may donate organs because it will benefit the community.

Diet and nutrition

General, no prohibitions unless prohibited by religious beliefs (pork not eaten by Muslims).

Most Muslims do not eat pork. Avoid icy drinks when sick or hot/cold drinks together.

Death/dying & birth

Reluctant to donate organs. Death is a universal experience transcending racial, religious, and socioeconomic barriers.

Colostrum is believed to be harmful to infants.

Misc.

Silence may indicate lack of trust toward the caregiver.

Supportive family members may need to be encouraged to take breaks from caregiving. (Text continued on following page)

BASICS


Page 5 11:22 AM 4/6/07 01White (F)-01

Cultural Diversity

Characteristics Eye contact Touching

Gender role differences Religion and spirituality Blood/organ donation Diet and nutrition Death/dying & birth

BASICS

Misc.

Bosnian Americans

Native Americans

Looking straight into someone’s eyes during a It is important to maintain sustained eye contact during conversations. conversation shows honesty and frankness. Light touch handshake is OK. Shaking hands is OK. Strict Muslims do not Maintain a respectful distance allow male nurses to examine women. while interacting with the patient. Varies from nation to nation. Traditionally, a patriarchal family structure. Majority are Muslim or Christian, a few may May be traditional Native American belief or Christian. be Jewish. Organ donation and receiving blood products Blood and organ donation is generally not desired, but may are acceptable. be open to discussion. Restrictions will vary with Pork is prohibited by Muslims. Medications religious/spiritual beliefs. should not contain alcohol (also prohibited by Muslims). Many visitors can be expected. No cremation Full family involvement occurs throughout all stages of life. is allowed. May only want females present Circumcision may be refused. during delivery of a child. Permanent life support is unacceptable. Most Older adults may prefer the use of “American Indian” over Native consider it shameful to accept Medicaid. American. (Text continued on following page)

6


Page 6 11:22 AM 4/6/07 01White (F)-01

Cultural Diversity (Continued)

Characteristics Eye contact

7

Touching Gender role differences Religion and spirituality Blood/organ donation Diet and nutrition Death/dying & birth Misc.

Mexican Americans May avoid direct eye contact with authority figures (health-care providers included). Except for handshaking, touching may be considered disrespectful. Entire family shares equally in decision-making. Primary religion is Roman Catholic.

Russian Americans Direct eye contact is OK. Nodding signifies approval. Touching is OK once familiarity or friendship has been established. Typically, both men and women share in decision-making. Primary religions are Jewish, Eastern Orthodox, and Christian. Many may not practice a faith due to past oppression. May refuse organ donation based on belief that the body is sacred. Drinks with ice should not be served.

Will vary; may be against organ donation. Catholics may refrain from eating meat on Fridays and during Lent. Strong family support during labor. Father may not attend birth, but the Most are very expressive during closest female family member usually bereavement. does. Silence may sometimes indicate a Interpreters should be used whenever disagreement with the plan of possible. care.

BASICS


Page 7 11:22 AM 4/6/07 01White (F)-01

Cultural Diversity (Continued)

01White (F)-01

4/6/07

11:22 AM

Page 8


BASICS

Weight, Temperature, and Length Conversions Weight Lb

Kg

300 275 250 225 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10

136.4 125.0 113.6 102.3 98.5 90.9 86.4 81.8 77.3 72.7 68.2 63.6 59.1 54.5 50.0 45.5 40.9 36.4 31.8 27.3 22.7 18.2 12.6 9.1 4.5

Temperature F 212 108 107 106 105 104 103 102 101 100 99 98.6 98 97 96 95 94 93 92 91 90 89 88 87 86

C 100 42.2 41.6 41.1 40.6 40.0 39.4 38.9 38.3 37.8 37.2 37.0 36.7 36.7 35.6 35.0 34.4 34.0 33.3 32.8 32.1 31.7 31.1 30.6 30.0

Length Cm

Inches

Feet and Inches

142 145 147 150 152 155 157 160 163 165 168 170 173 175 178 180 183 185 188 191 193 196 198 201 203

56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80

4′8′′ 4′9′′ 4′10′′ 4′11′′ 5′0′′ 5′1′′ 5′2′′ 5′3′′ 5′4′′ 5′5′′ 5′6′′ 5′7′′ 5′8′′ 5′9′′ 5′10′′ 5′11′′ 6′0′′ 6′1′′ 6′2′′ 6′3′′ 6′4′′ 6′5′′ 6′6′′ 6′7′′ 6′8′′


8

01White (F)-01

4/6/07

11:22 AM

Page 9


9 Weight, Temperature, and Length Conversions (Continued) Weight Lb 5 2.2 2 1

Temperature

Kg 2.3 1 0.9 0.45

F 85 75 74 73 72 71 70 69 68 32

C 29.4 23.9 23.3 22.8 22.2 21.7 21.1 20.6 19.9 0.0

Length Cm 206 208

Inches 81 82

Feet and Inches 6′9′′ 6′10′′

Lb Kg 2.2 Lb/Kg 9 F C 32 5

Kg Lb 0.45 Kg/Lb 5 C (F 32) 9

inches cm 0.394 inches/cm

cm inches 2.54 cm/inch

Pressure Conversions (60F) cmH2O

mmHg

KPa

5

3.68

0.49

10

7.35

0.98

15

11.03

1.47

20

14.71

1.96

25 30 35

18.38 22.06 25.74

2.45 2.94 3.43 (Text continued on following page)

BASICS

01White (F)-01

BASICS

4/6/07

11:22 AM

Page 10


Pressure Conversions (60F) (Continued) cmH2O

mmHg

40 45 50 55 60 65 70 75 80 85 90 95 100

KPa

29.41 33.09 36.76 40.44 44.11 47.79 51.47 55.15 58.82 62.5 66.17 69.85 73.53

3.92 4.41 4.90 5.39 5.88 6.37 6.86 7.35 7.84 8.33 8.82 9.31 9.80

1 cmH2O 0.098 KPa

1 KPa 10.21 cmH2O

1 mmHg 1.36 cmH2O

1 cmH2O 0.737 mmHg

ATPS BTPS BTPS ATPS

STPD ATPS

ATPS STPD PB PH2o PB 47 PB PH2O 760

310 273 T

273 273 T

PB Barometric pressure PH2O Partial pressure of H2O at spirometer temperature Partial pressure of H2O at body temperature and pressure saturated 310 Body temperature in Kelvin T Spirometer temperature (C)

47

10

02White (F)-02

4/6/07

5:05 PM

Page 11


11 Patient Interview Purpose The patient interview facilitates the collection of subjective information regarding the patient’s present illness while establishing a professional rapport and trust with the patient.

Structure of the Interview ■ Project a genuine interest in the patient ■ Be sensitive to the patient’s concerns ■ Give undivided attention to the patient and his or her responses ■ Use eye contact effectively ■ Introduction ■ Be professional (dress, mannerisms, respect, etc.) ■ Introduce yourself to the patient using last names (Mr. Smith, I am Mrs. Lanker from respiratory care.) ■ Use eye contact ■ Professionalism ■ Conduct the interview seated beside the patient facing him or her ■ The patient should be seated upright with his or her eyes at an elevation higher than yours ■ Maintain privacy ■ Respect the patient’s beliefs and attitudes ■ Use open-ended questions (Tell me, how is your breathing this morning?) ■ Use reflection in your responses (So your chest feels tight.) ■ Be empathetic

BED ASSESS

02White (F)-02

BED ASSESS

4/6/07

5:05 PM

Page 12


History Taking ■ Biographical ■ Age, gender, occupation, race/culture ■ Chief complaint ■ What resulted in the patient seeking medical attention? ■ What are the symptoms that caused the patient to seek medical attention? ■ Are there any associated symptoms (sweats/chills, fever, cough, etc.)? ■ Onset, duration, severity? ■ History of present illness ■ Detailed description of each symptom described in the chief complaint ■ P, Q, R, S, T ◆ P (Provokes/Point): What causes it, what makes it better, where is it? ◆ Q (Quality): Dull, achy, how much is involved, how does it look, how does it feel? ◆ R (Region/Radiation): Where does it radiate or spread? What makes it better? What makes it worse? ◆ S (Severity): Lichert scale 1 (no pain) to 10 (worst pain). ◆ T (Timing): When did it start? Is it constant? Is it sudden or gradual? ■ Past medical history ■ Childhood illnesses ■ Hospitalizations (injuries, accidents, emergent conditions, etc.) ■ Surgeries (elective, emergency, etc.) ■ Allergies, immunizations ■ Current medications (prescribed and over-the-counter) ■ Social history ◆ Smoking: How long? What (cigarettes, cigars, pipe, etc.)? Have you quit? How long? ◆ Alcohol: How long? What (liquor, wine, beer)? How often? How much? How long? ◆ Drug use: What? How often? How long?

12

02White (F)-02

4/6/07

5:05 PM

Page 13


13 ■ Family history ◆ Family history for chronic lung disease (asthma, emphysema, bronchitis, cystic fibrosis)? ◆ Family history for heart disease? ◆ Family history for hypertension? ◆ Family history for renal disease? ◆ Family history for cancer? ■ Occupational/environmental history ◆ Work: Shipyard, mining, farming, foundry work, mill work, insulation installation, welding, chemical exposure, textile work, etc. ◆ Home: Air conditioning, evaporative cooling, humidifier, molds, insulation, plants, smoking, wood stove use ◆ Geographical: Histoplasmosis, coccidioidomycosis, blastomycosis

Vital Signs Vital Signs Assess vital signs upon admission as ordered; on change in status, with chest pain or any abnormal sensation; before and after administration of blood products or medications that can cause cardiovascular or respiratory changes; before and after any intervention that can affect the cardiovascular or respiratory system. Vital signs should include temperature (T), heart rate (HR), respiratory rate (RR), blood pressure (BP), SpO2, and pain assessment.

BED ASSESS

BED ASSESS

Age Preemie Term 36.8

6 mo

1 yr

3 yr

6 yr

9 yr

37.7

37.7

37.7

37

37

12 yr 15 yr 37

37

Adult Elderly

T

36.8

37

36

HR

140

RR

40–60

30–80

30–60

20–40

20–40

15–25

15–25

BP

73/55

73/55

73/55

90/55

90/55

95/57

95/57 120/80 120/80 120/80 120/80

SpO2

95%

95%

95%

95%

95%

95% 95 % 95% 95% 95%

80–180 80–140 80–140 80–140 75–120 50–90 50–90 50–90 60–100 60–100 15–24 15–20 12–20

15–20

95%

14


Page 14 5:05 PM 4/6/07 02White (F)-02

Normal Ranges

02White (F)-02

4/6/07

5:05 PM

Page 15


15 Head and Neck Assessment ■ Head—Facial expressions, cyanosis, pursed lip breathing, nasal flaring, eyes (pupil size and reaction)? ■ Neck—Jugular venous distension, use of accessory muscles, tracheal position, lymph node palpation?

Physical Examination of the Chest Inspection ■ Respiratory rate: Normal, tachypnea, bradypnea? ■ Rhythm: Regular, irregular? ■ Pattern: Eupnea, hyperpnea, hypopnea, Kussmaul’s, CheyneStokes, Biot’s ■ Chest conformation: A-P diameter, kyphosis, scoliosis, lordosis, kyphoscoliosis, pectus? ■ Digital clubbing?

BED ASSESS

02White (F)-02

BED ASSESS

4/6/07

5:05 PM


Ventilatory Patterns

Normal (Eupnea)

Cheyne-Stokes

Biot’s

Kussmaul’s Palpation ■ ■ ■ ■ ■

Tracheal position: Midline, deviated right or left? Areas of tenderness? Symmetry: Do the hands move uniformly? Tactile fremitus: Present or absent? Subcutaneous emphysema present?

16

Page 16

02White (F)-02

4/6/07

5:05 PM


17 Assessment of Chest Symmetry

Anterior

Posterior

BED ASSESS

Page 17

02White (F)-02

BED ASSESS

4/6/07

5:05 PM

Page 18


Percussion ■ ■ ■ ■

Hyperresonance: Air trapping? Pneumothorax? Resonance: Normal air/tissue density? Dullness: Consolidation? Atelectasis? Pleural fluid? Flatness: Pleural effusion? Pneumonectomy?

Auscultation ■ Vesicular: Low pitched and soft with inspiration longer than expiration. Normal over most of the lung fields. ■ Bronchial: Harsh, loud and higher pitched with expiration longer than inspiration. Normal over the manubrium. ■ Bronchovesicular: Moderate intensity and pitch with equal inspiratory and expiratory phases. Over sternum and lung apices. ■ Crackles: Discontinuous (starts and stops) fine, medium, or coarse (inspiratory or expiratory). Can be caused by alveoli opening (fine), fluid in bronchioles (medium), and fluid in large airways (coarse). ■ Wheezes: Continuous “musical” sound (inspiratory or expiratory). Caused by air flowing through narrowed airway lumen. A wheeze will have a higher pitch if the narrowed lumen is very small. Wheezing should be described as inspiratory, expiratory, monophonic (single pitch), or polyphonic (multiple pitches). Polyphonic wheezing occurs during the expiratory phase. ■ Rhonchi: Coarse, wet, low-pitched continuous sounds produced by large amounts of secretions in the airways. Rhonchi may clear if the patient is asked to cough. ■ Rub: Grating or creaking sound (like leather rubbing). Caused by inflamed pleural layers or pleural irritation.

18

02White (F)-02

4/6/07

5:05 PM


19 Positions Used in Chest Auscultation 1

1 2

2 3

3 4

4 5

5

Anterior 1

1 2

2

4

4 5

3

3 5

6

6

7

7 8 9

Posterior

BED ASSESS

8 9

Page 19

02White (F)-02

4/6/07

5:05 PM

Page 20


BED ASSESS

Sputum/Cough ■ Cough—Duration (acute 3 weeks, chronic 3 weeks or recurrent), productive, nonproductive, time of occurrence? ■ Sputum—Amount (30 mL/day, 30 mL/day), color, consistency, odor, hemoptysis?

Ventilation Assessment ■ VE, VT, and Frequency ■ Minute Volume (VE)—The volume exhaled or inhaled in 1 minute ◆ Normal: 5–7 L/min (adult) ■ Tidal Volume (VT)—The resting volume inhaled or exhaled during each breath ◆ Normal: 4–7 mL/kg ■ Frequency (rate)—The number of breaths per minute. Normals: ◆ Term infant: 30–80 ◆ 6-month-old: 30–60 ◆ Pediatric: 20–40 ◆ Adolescent: 15–25 ◆ Adult: 12–20 ■ Rapid Shallow Breathing Index (frequency/tidal volume [L]) ■ Normal: 100 ■ PaCO2 ■ Normal: 35–45 mmHg ■ PEtCO2 ■ Normal: 35–43 mmHg ■ Deadspace (VD ana, VD/VT) ■ Anatomic: Normal 1 mL/Lb body weight VD 1 mL Body Weight (Lb) ■ VD/VT: Normal 0.25–0.35 VD / VT ■ Alveolar Ventilation

PaCO2 PECO2 PaCO2

VA (VD / VT VT)f

20

02White (F)-02

4/6/07

5:05 PM

Page 21


21 Oxygenation Assessment PaCO2 0.8

Alveolar air

PAO2 FIO2(PB 47 mmHg)

Oxygen content

CaO2 SaO2 (Hb 1.34) (PaO2 0.003) Normal: 15–24 mL/dL PaO2: 80–100 mmHg SpO2: 90%

Oxygen delivery

DO2 QT (CaO2 10) Normal: 1000 mL/min SvO2 (Hb 1.34) (PvO2 0.003) Normal: 12–15 mL/dL CaO2 – CvO2 Normal: 4–6 mL/dL PaO2/FIO2 Normal: 200

Note: Only calculate at FIO2 of 0.21 or 1.0

Venous oxygen content Arterial-venous oxygen content difference

PaO2/PAO2 Normal: 0.8–0.9 Oxygen consumption

VO2 QT (Ca-vO2 10) Normal: 250 mL/min

Oxygen extraction ratio

O2 ER

End capillary oxygen content

CcO2 (Hb 1.34) (PAO2 0.003)

Pulmonary shunt

CaO2 CvO2 CaO2 Normal: 0.25

CcO2 CaO2 Qs /QT CcO CvO 2 2 Normal: 0.20

BED ASSESS


Inspection

Palpation

Ventilation

Percussion Auscultation VT f

↓ Normal or Normal or ↓Breath fremitus dull sounds, crackles, rhonchi & Pursed lip wheezing breathing

Bronchi- Use of accessory tis muscles

PaCO2

Oxygenation Indices SpO2 CaO2 QS/QT

↑ ↑ ↑ (chronic)

↓

↓

↑

Asthma

Use of accessory muscles

↓ Normal or Normal or Wheezing, fremitus hyperrecrackles sonant

Pursed lip breathing

↑ ↑ ↓ (early)

↓

↓

↑

↓

↓

↑

22

Page 22 5:05 PM

Physical Findings

↑ A-P Dia

4/6/07

↑ (severe or late)

↑ A-P Dia

BED ASSESS

02White (F)-02

Disease State Summary

Emphysema

Use of accessory muscles ↑ A-P Dia

↓ Normal or Hyperreso- Crackles & fremitus nant wheezing

↑ ↑ ↑


Ventilation

Inspection Palpation Percussion Auscultation VT f PaCO2 Cystic Fibrosis

Use of ac- ↑Fremitus Hyper↓Breath cessory resonant sounds, muscles crackles, & rhonchi ↑ A-P Dia

Pneumonia

Dyspnea

↑Fremitus Dullness

Pulmonary Edema

Dyspnea

Pulmonary Embolus

Atelectasis

Oxygenation Indices SpO2 CaO2 QS/QT

↑ ↑ ↑

↓

↓

↑

↓Breath sounds, crackles, & rhonchi

↓ ↑ ↓

↓

↓

↑


↓Breath sounds, crackles, rhonchi & wheezing

↓ ↑ ↓

↓

↓

↑

Dyspnea

Normal

↓ ↑ ↓

↓

↓

↑

Dyspnea


Wheezing, crackles, pleural friction rub ↓Breath sounds, crackles

↓ ↑ ↑ (severe)

↓

↓

↑

Normal

BED ASSESS

Physical Findings

23

Page 23 5:05 PM 4/6/07 02White (F)-02

Disease State Summary

02White (F)-02

BED ASSESS

4/6/07

5:05 PM

Page 24


Cardiac Assessment Capillary Refill ■ Normal: 3 seconds ■ Increased: 3 seconds (low cardiac output or decreased peripheral perfusion)

Heart Rate ■ Normals ■ Newborn 80–180/min ■ 1 year 80–140/min ■ 2 years 80–140/min ■ 6 years 75–120/min ■ 10 years 50–90/min ■ 16 years 50–90/min ■ Adult 60–100/min ■ Geriatric 60–100/min ■ Points of palpation: radial, brachial, femoral, carotid, popliteal, posterior tibial, dorsal pedal

Blood Pressure ■ Normals ■ Newborn ■ 1 year ■ 2 years ■ 6 years ■ 10 years ■ 16 years ■ Adult ■ Geriatric

73/55 mmHg 90/55 mmHg 90/55 mmHg 95/57 mmHg 95/57 mmHg 120/80 mmHg 120/80 mmHg 120/80 mmHg

24

02White (F)-02

4/6/07

5:05 PM

Page 25


25 Cardiac Palpation ■ Point of Maximal Impulse (PMI) – 5th intercostal space midclavicular line (left ventricular contraction) ■ Left shift—cardiomegaly ■ Left sternal border—right ventricular hypertrophy (COPD) ■ Reduced—emphysema, hyperinflation ■ Lobar collapse—shifts toward collapse ■ Pneumothorax—shifts away from pneumothorax ■ Pulmonic palpation—2nd intercostal space at the sternal border ■ Increased—pulmonary hypertension

Cardiac Auscultation ■ Normal heart sounds: ■ S1—Tricuspid and mitral valve closure during ventricular contraction. Auscultated at lower left sternal border. ■ S2—Pulmonic and aortic valve closure during diastole. Auscultated at 2nd intercostal space at the sternal border. ■ S3—Produced by rapid ventricular filling following systole. Auscultated at the apex of the heart (5th intercostal space midclavicular line). ■ S4—Presystolic gallop. Auscultated late in diastole at the apex (5th intercostal space midclavicular line). Lowfrequency sound and often transient, caused by decreased ventricular compliance or in increased diastolic volume.

BED ASSESS

02White (F)-02

BED ASSESS

4/6/07

5:05 PM

Page 26


Positions used in heart auscultation

Pulmonary

Aortic

Tricuspid

Mitral

■ Abnormal auscultatory heart sounds: ■ Split S1—Delayed closure between the tricuspid and mitral valves (abnormally long S1 interval) can be caused by right bundle branch block, preventricular contractions (PVCs), or ventricular tachycardia. ■ Split S2—Delayed closure between the pulmonic and aortic valves (abnormally long S2 interval) can be caused by atrial septal defect, ventricular septal defect, pulmonic stenosis, pulmonary embolism, and a right bundle branch block. ■ Click—Early systolic high-frequency sound caused by rapid opening of the aortic valve. Late systolic (after S1) caused by mitral valve prolapse. ■ Snap—High-frequency sound occurring after S2 frequently caused by mitral stenosis.

26

02White (F)-02

4/6/07

5:05 PM

Page 27


27 ■ Murmurs—Sustained heart sounds caused by turbulent blood flow through the heart. ◆ Presystolic murmur: Heard at the start of S1 with its peak occurring in the first third of systole. Caused by mitral stenosis or increased flow through the pulmonic valve. ◆ Midsystolic murmur: Heard just after S1 peaking at midsystole. Caused by narrowed aortic or pulmonic valve. ◆ Late systolic murmur: Heard during late systole. Caused by mitral valve prolapse or tricuspid valve defects. ■ Early diastolic murmur: Heard at the start of S2 peaking in the first part of diastole. Caused by aortic regurgitation. ■ Mid-diastolic murmur: Heart after S2 peaking at mid diastole. This is a low-frequency sound, caused by mitral stenosis and best heard at the apex. ■ Late diastolic murmur: Heard late in diastole, often extending into S1, can be caused by mitral and tricuspid stenosis. ■ Bruits: Auscultatory heart sounds heard over the neck (carotid arteries). The sound is caused by turbulence (obstruction to blood flow) and is of mixed frequency.

Cardiac Enzymes Enzyme Troponin (TnI) Troponin (TnT) Creatine phosphokinase (CPK) CPK-MB

Normal 0.0–0.1 ng/mL 0.18 ng/mL 150 U/L 3 ng/mL

Neurological Assessment ■ Mental status: Alert, confused, lethargic, comatose ■ Motor ability: ■ Grip Strength: Ask patient to grip your hands. Is the grip equal? Ask the patient to push/pull your hands. Is it equal? ■ Feet: Ask the patient to push/pull your hands. Is it equal?

BED ASSESS

02White (F)-02

4/6/07

5:05 PM

Page 28


BED ASSESS

■ Tremors, tics, mannerisms, gestures, gait hyperactivity, restlessness, agitation echopraxia, rigidity, aggressiveness ■ Posture: decorticate (arms rigidly flexed, legs extended), decerebrate (arms extended [pronated] and legs extended) ■ Pupil size: (See Vital Signs) ■ Glasgow Coma Score (see Tab 5, Critical Care)

Nutritional Assessment Body Mass Index weight in lbs. BMI 703 (height in inches)2

Body Mass Index

Weight Status

18.5 18.5–24.9 25.0–29.9 30

Underweight Normal Overweight Obese

Body Fat

Skinfold Thickness Use calipers to measure skinfold thickness at the biceps, triceps, subscapular, and suprailiac regions. Tables are used to translate the data into relative percentage of body fat. Skinfold thickness measurements are one way to estimate total body fat.

Maximum Percentage of Body Fat 20 years of age 20–22 years of age 23–25 years of age 25–29 years of age 30 years of age

17 % 18 % 19 % 20 % 22 %

28

02White (F)-02

4/6/07

5:05 PM

Page 29


29 Lab Tests

Serum Albumin Measure of the protein fraction in the blood that corresponds to protein reserves in the muscles. The test can be used to screen protein depletion. However, 1/2 life is long (20 days) so values can be slow to change with changes in nutritional intake.

Serum Albumin Level

Assessment

3.5–5.0 gm/dL 2.5 gm/dL

Normal Deficient

Thyroxin-binding Prealbumin This value quickly reflects changes in nutrition (1/2 life 2 days).

Thyroxin-binding Prealbumin (TBP) Level

Assessment

10–20 mg/dL 10 mg/dL

Normal Deficient

Retinol-binding Protein A measure of a transport protein of retinol in the plasma (alpha 1-globulin). This has a short 1/2 life (12 hours), and quickly reflects changes in nutritional status.

Retinol-binding Protein (RBP) 3–6 micro gm/dL 3 micro gm/dL

Assessment Normal Deficient

Urea Nitrogen Measurement of nitrogen content of the urine. An increase in urea nitrogen reflects in increase in protein catabolism.

Urea Nitrogen 8–25 mg/dL 25 mg/dL

BED ASSESS

Assessment Normal Increased catabolism of proteins

Physician Date

Race/Culture

Time

Gender

Admission DX

RCP

HISTORY

Past Medical HX

HX of Present Illness

Current Medications:

30

Height

Age

Chief Complaint

BED ASSESS

Weight

Room

4/6/07


Page 30

Name

02White (F)-02

5:05 PM

Basic Assessment

Social History Smoker: Yes ■ No ■ Cigarettes? Yes ■ packs/day ____ How many years? ____ Cigars? Yes ■ How many/day? _____ How many years? _____ Other? ________________ Alcohol use? Yes ■ No ■ What and how much/day? ____________ Nonprescription drug use? Yes ■ What and how often? ________________

No ■


VITAL SIGNS

HEAD/NECK

MENTAL STATUS

Temp

Head

Alert:

SpO2

Neck: JVP? Yes ■ No ■ Lymph enlargement? Yes ■ No ■ Pupils

PHYSICAL EXAMINATION INSPECTION Rate: normal tachypnea bradypnea Rhythm: normal irregular Pattern: ______________________________

PALPATION Tracheal Pos: midline L R Areas of Tenderness? ______ Symmetry? ___________

Increased A-P Dia?

Yes ■

No ■

Kyphosis? ■ Lordosis? ■ Scoliosis? ■ Yes ■

No ■

Pursed lip breathing? Yes ■

No ■

Cyanosis?

Yes ■

No ■

Sub-Q Air? Yes ■

No ■

Fremitus?

Yes ■ No ■

Confused: Yes ■ No ■ Lethargic: Yes ■ No ■ Comatose: Yes ■ No ■ PERCUSSION Location Hyperresonant ________ Resonant _____________ Dullness ______________ Flatness ______________

BED ASSESS

Heart Rate BP Resp Rate

31

Page 31 5:05 PM 4/6/07 02White (F)-02

Basic Assessment

OXYGENATION

VE

CaO2

VT

SpO2

f

PaO2

How much?

RSBI

PaO2/ FIO2

Color/Odor?

PaCO2

Ca-vO2

VD/VT

QS/QT

CARDIAC ASSESSMENT

NEUROLOGICAL ASSESSMENT

NUTRITIONAL ASSESSMENT

Capillary Refill: Normal Prolonged

Grip Strength: Normal

Weak

BMI:

Heart Rate

Push Pull: Normal

Weak

% Body Fat:

BP

Tremors, tics, etc

Serum Albumin

Posture:

TBP:_______

GCW:

RBP: ________

Cough?

BED ASSESS

Yes

No

How long? Productive?

PMI: Normal

Yes

Yes

L

No

No

R

Auscultation: Bruits:

Yes

No

Urea Nitrogen: ___________

32


Page 32 5:05 PM

VENTILATION

SPUTUM/COUGH

Hemoptysis?

4/6/07 02White (F)-02

Basic Assessment


CHEST X-RAY

PULMONARY FUNCTION

pH

FVC

PaCO2

FEV1

HCO3

FEV1/FVC

PaO2

PEF

BE

DLCO

SaO2

FRC

Hb

RV

COHb

TLC

MetHb

RV/TLC

Current O2

BED ASSESS

ARTERIAL BLOOD GASES

33

Page 33 5:05 PM 4/6/07 02White (F)-02

Basic Assessment

ADV ASSESS

Complete Blood Count

Men

Women

Differential

%

Red blood cells (RBC)

4.6–6.2 million/dL

4.6–6.2 million/dL

Neutrophils

40–75%

Hemoglobin (Hb)

13.5–16.5 gm/dL

12.0–15.0 gm/dL

Bands

0–5%

Hematocrit (Hct)

40–54%

38–47%

Eosinophils

0–6%

Mean cell volume (MCV)

80–90 3

80–90 3

Basophils

0–1%

Mean cell hemoglobin (MCH)

21–31 pgm

21–31 pgm

Lymphocytes

20–45%

Mean cell hemoglobin concentration

32–36%

32–36%

Monocytes

2–10%

Platelets

150,000–400,000/ mm3

150,000– 400,000/mm3

34


Page 34 11:18 AM 4/6/07 03White (F)-03

Hematology

03White (F)-03

4/6/07

11:18 AM

Page 35


35 Chemistry

Sodium (Na ) Potassium (K) Chloride (Cl–) Carbon dioxide (CO2) Blood urea nitrogen (BUN) Creatine Total protein Albumin Cholesterol Low-density lipoproteins (LDL) High-density lipoproteins (HDL) Glucose

137–147 mEq/L 3.5–4.8 mEq/L 98–105 mEq/L 25–33 mEq/L 7–20 mEq/L 0.7–1.3 mg/dL 6.3–7.9 gm/dL 3.5–5.0 gm/dL 150–220 mg/dL 130 mg/dL 30–75 mg/dL 70–105 mg/dL

Collection and Evaluation of Pulmonary Secretions 1. Have the patient rinse his or her mouth or preferably brush teeth. 2. Have the patient strongly cough to attempt to expectorate a deep pulmonary sample. 3. If the patient is unable to bring up a sample, administer an SVN or large volume nebulizer treatment with 10% saline (hypertonic saline), and repeat step 2. 4. If the patient is unable to cooperate or is unable to expectorate an adequate sample, a sample can be obtained by nasotracheal suctioning or bronchoscopy. 5. Have the laboratory perform a Gram stain and look for squamous epithelial cells (saliva). If there is a heavy concentration of squamous epithelial cells, re-obtain the sample.

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 36


ADV ASSESS

Microbiology Microbiological assessment (bacteriology) is performed on body fluid/substance samples to determine the cause of infection (culture) and what antibiotics are effective (sensitivity). Besides bacteria, samples can be tested for fungi, protozoa, and viruses.

Gram-Positive Bacteria Streptococcus Staphylococcus Mycobacterium tuberculosis Gram-Negative Bacteria Klebsiella Haemophilus influenzae Legionella pneumophila

Common Viruses Influenza virus Adenovirus Respiratory syncytial virus Parainfluenza virus Cytomegalovirus

Common Fungi Aspergillus Microsporum Histoplasma Blastomyces Coccidioides

Common Yeast Candida

Common Protozoa Pneumocystis carinii

Histology/Cytology Histology is the study of the microscopic structure of tissue, whereas cytology is the study of cellular structure.

36

03White (F)-03

4/6/07

11:18 AM

Page 37


37 Sample Preparation Testing

Preparation

Microbiology Cytology Histology

0.9% saline Ringer’s lactate 95% alcohol Saccomanno’s solution Formalin

Skin Testing ■ Skin testing is the diagnosis of disease by subcutaneous injection of small amounts of protein essence of the organism. Tuberculosis (TB), coccidioidomycosis, histoplasmosis, sarcoidosis, and allergies may be diagnosed using this technique. ■ TB Testing—Skin testing for TB is performed by injecting 0.1 mL of purified protein derivative (PPD) subcutaneously. The test is read between 48 and 72 hours following injection. The injection site is evaluated for a wheal and redness, indicating a positive test.

Arterial Blood Gas Interpretation Drawing Arterial Blood Gases 1. Correctly identify the patient. 2. Verify correct oxygen/ventilator settings and record patient’s temperature. 3. Gather required equipment: ■ Blood gas collection kit (syringe, needle, antiseptic wipes [alcohol and iodine-based], stopper, container for ice) ■ Exam gloves ■ Eye protection (goggles) ■ Ice ■ Required paper work

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 38


ADV ASSESS

4. Perform modified Allen test for collateral circulation (radial puncture). 5. Don protective equipment (gloves and goggles). 6. Prep puncture site (antiseptic wipe). 7. Palpate pulse. 8. Puncture site between a 30 and 45 angle. 9. Draw sample. 10. Hold pressure on puncture site for 5 minutes following collection. 11. Expel all air from the sample. 12. Cap and ice sample.

Arterial Blood Gas Normal Values Value

Range

pH PaCO2 HCO3 BE PaO2

7.35–7.45 35–45 mmHg 22–26 mEq/L 2 80–100 mmHg

To accurately interpret arterial blood gas results, one must first memorize the normal values. Only after the normal values are committed to memory can blood gases be interpreted.

Steps to Interpret an Arterial Blood Gas

Respiratory Disturbances 1. Evaluate the pH. Alkalosis? Acidosis? 2. Evaluate the PaCO2. Is the PaCO2 moving opposite the pH? If yes, it’s a respiratory acid/base disturbance. 3. If it is a respiratory acidosis, determine if it’s acute or chronic: ■ Acute: If the PaCO2 increases by 10 mmHg the pH should decrease by 0.08 ■ Chronic: If the PaCO2 increases by 10 mmHg the pH should decrease by 0.03 4. If it is a respiratory alkalosis, determine if it’s acute or chronic:

38

03White (F)-03

4/6/07

11:18 AM

Page 39


39 ■ Acute: For each 10 mmHg decrease in PaCO2 the pH should increase by 0.08 ■ Chronic: For each 10 mmHg decrease in PaCO2 the pH should increase by 0.03

Metabolic Disturbances 1. Evaluate the pH. Alkalosis? Acidosis? 2. Evaluate the PaCO2. Is the PaCO2 moving the same direction as the pH? If yes, it’s a metabolic acid/base disturbance.

Metabolic Acidosis If it’s a metabolic acidosis: 1. Determine if it’s an anion gap (AG) acidosis: ■ AG Na (CI HCO3 ) ■ Note: The HCO3 must be from an electrolyte panel not the blood gas data. ■ Normal AG 8 – 12 (2) ■ If the AG is 12 then it’s an anion gap acidosis. 2. Determine the respiratory compensation using Winter’s Formula. ■ PaCO2 1.5 (HCO3) 8 (2) ■ Note: The HCO3 must be from an electrolyte panel not the blood gas data. ■ If the PaCO2 is less than expected (Winter’s Formula), there is a primary respiratory alkalosis. ■ If the PaCO2 is greater than expected (Winter’s Formula), there is a primary respiratory acidosis. 3. Determine the Delta gap: ■ Corrected HCO3 (HCO3 [AG 12]) ■ If the Delta gap is 24 it’s a nonanion gap (AG) acidosis. ■ If the Delta gap is 24 there is a metabolic acidosis.

Metabolic Alkalosis

■ Compensation for metabolic alkalosis is not as linear as in metabolic acidosis (Note: Don’t use Winter’s Formula!). ■ Compensation will tend to depress the respiratory drive, increasing the PaCO2. ■ Calculate the expected PaCO2. ■ PaCO2 0.9 (HCO3) 9 ■ Note: The HCO3 must be from an electrolyte panel not the blood gas data.

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 40


ADV ASSESS

■ If the PaCO2 is than expected, there is an underlying respiratory alkalosis. ■ If the PaCO2 is than expected, there is an underlying respiratory acidosis.

Cautions/Pitfalls

1. Use the HCO3 from the electrolyte panel, not the calculated value from a blood gas. 2. Draw the ABG at the same time as the electrolyte panel. 3. Apply the formulas listed.

Respiratory Disturbance Etiologies Respiratory Acidosis Lung disease (COPD, pneumonia, etc.) Pleural disease (effusion, hemothorax, pneumothorax, etc.) Neuromuscular disorders (myopathies, neuropathies) CNS depression (sedatives, anesthesia, respiratory center lesions) Acute obstruction

Respiratory Alkalosis CNS disorders (CVA, tumor, infection) Hormones/Drugs (progesterone, salicylates, etc.) Fever (gram-negative sepsis) Hyperthyroidism Anxiety Pregnancy

Metabolic Acidosis Etiologies Anion Gap Acidosis

Nonanion Gap Acidosis Hyperalimentation Acetazolamide RTA (renal tubular acidosis) Diarrhea Urectosigmoidostomy Pancreatic fistula

Methanol Uremia (renal failure) DKA (diabetic ketoacidosis) Paraldehyde Inborn errors of metabolism (idiopathic) Lactic acidosis Ethylene glycol intoxication Salicylates

40

03White (F)-03

4/6/07

11:18 AM

Page 41


41 Metabolic Alkalosis Etiologies

■ Extracellular fluid volume depletion (vomiting, diuretic therapy, laxative abuse) ■ Severe potassium depletion ■ Mineralocorticoid excess syndrome (Cushing’s syndrome, ectopic adrenocorticotropic hormone) ■ Bartter’s syndrome

Evaluate the PaO2 ■ ■ ■ ■

PaO2 80–100 mmHg 60 mmHg PaO2 80 mmHg 40 mmHg PaO2 60 mmHg PaO2 40 mmHg

Normal Mild hypoxemia Moderate hypoxemia Severe hypoxemia

Chest X-Ray Interpretation Chest x-rays are produced by passing a form of ionizing radiation through the chest, exposing a film plate. The image formed is the result of the differing radio densities of the anatomy as the energy passes through the body.

Radiodensities of Common Materials Air

Least dense

Appears black on a chest x-ray

Water

More dense than air

Appears gray on a chest x-ray

Fat

More dense than water

Appears lighter gray than water on a chest x-ray

Bone

More dense than fat

Appears white on a chest x-ray

Plastic

Similar density to fat

Appears lighter gray on a chest x-ray

Metal

Most radiodense

Appears bright white on a chest x-ray

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 42


ADV ASSESS

Common Radiographic Views

Posterior–Anterior (PA) X-ray tube 72 inches

Film plate

Preferred view because the cardiac silhouette is not magnified.

Anterior–Posterior (AP) X-ray tube 72 inches

Film plate

Common view of a portable chest x-ray; the cardiac silhouette is magnified.

42

03White (F)-03

4/6/07

11:18 AM

Page 43


43 Lateral X-ray tube

Film plate 72 inches

Evaluating a Chest X-Ray

Determine Technical Quality

■ Rotation—Is the spine centered between the necks of the clavicles on the PA or AP view? If not, is the rotation to the right or left? ■ Penetration—Can the vertebral columns be faintly seen through the center of the chest? If they are very distinct, it’s overpenetrated. If you can’t see them at all, it’s underpenetrated.

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 44


ADV ASSESS

Chest X-Ray Evaluation (Outside-In Approach) Extrathoracic structures

Evaluate white tissue density against the black air space surrounding the body. Look for subcutaneous air apically (air migrates superiorly).

Bones

Trace each rib, the clavicles, and sternum looking for fractures, costochondral separation. Look for spinal fractures, scoliosis, or kyphoscoliosis.

Pleura

Evaluate the pleura for thickening or plaques (increased density). Look for pleural air (black w/o lung markings) or fluid (white water/fluid density).

Diaphragms

Should be “dome” shaped with right slightly higher than the left. Check the costophrenic angle for blunting (pleural fluid).

Lung parenchyma

If eight ribs overlie the lung fields it’s a good inspiration. More than 10 ribs is hyperinflation. Look for areas of increased density.

Hilum

Increased density due to vascular volume. Is it engorged (possible CHF)?

Heart

Cardiac silhouette should be less than 1 /2 the diameter of the chest. Has a heart border been obscured (possible pneumonia)?

Trachea

Should be mid-line to about the fourth rib. Is it shifted (possible pneumothorax or atelectasis)?

Right and left mainstem bronchi

Carina should be evident with right mainstem bronchi branching at a lesser angle than the left.

44

03White (F)-03

4/6/07

11:18 AM

Page 45


45 Common Abnormalities Volume changes Volume increase

Volume decrease

Fluid changes

Foreign objects

ADV ASSESS

Hyperinflation (COPD): Flattened diaphragms, increased rib spacing, and darker appearance. Increased AP diameter and retrosternal airspace (lateral). Atelectasis: Elevated diaphragm on affected side. Shift of mediastinum to affected side. Increased radiodensity. Pneumothorax: Reduction in volume on affected side. Loss of lung markings in region of free air. Consolidation: Increased radiodensity (lighter than normal), often more lobar (compare PA with lateral). Pleural effusion: Blunting of costophrenic angles (PA) and posterior (lateral). A lateral decubitus projection can help to quantify. Congestive heart failure (CHF): Enlarged left ventricle (early). Increased hilar congestion. Increased fluid density with Kerley B lines along the right base. Increased size of heart silhouette. Pulmonary edema: Diffuse patchy infiltrate pattern. Chest tubes, nasogastric tubes, endotracheal tubes, feeding tubes, ECG leads, pacemakers, sternal clips, bullets, shotgun pellets.

03White (F)-03

4/6/07

11:18 AM

Page 46


ADV ASSESS

Electrocardiogram (ECG) Lead Placement

RA

LA

V1

V2

V6 V3 V4

RL

V5

LL

■ Limb leads—(right arm, left leg, left arm, left leg). Left and right hip may be substituted for lead placement on the legs. ■ Precordial leads—V1 and V2 (4th intercostal space adjacent to sternum), V4 (5th intercostal space mid-clavicular line), V3 (between V2 and V4), V5 (5th intercostal space anterior axillary line), V6 (5th intercostal space mid-axillary line)

46

03White (F)-03

4/6/07

11:18 AM

Page 47


47 Artifacts ■ Patient motion: irregular appearance of the ECG. Try to minimize motion if possible. ■ Wandering baseline: poor contact with electrodes. Change electrodes, prep skin with isopropyl alcohol. ■ 60 Hz artifact (common mode interference): poor ground, current leakage or faulty electrical outlet. Change outlets, ground ECG instrument, change leads.

ECG Assessment

■ Rate: ■ 60–100/min—Normal ■ 60—Bradycardia ■ 100—Tachycardia ■ Rhythm: Regular? Irregular? Regularly irregular? ■ P waves: One P wave with every QRS complex? ■ P-R Interval: 0.12–0.2 seconds ■ QRS: 0.08–0.12 seconds ■ ST Segment: Isoelectric? Depressed? Elevated? ■ Extra: Any abnormal or extra complexes?

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM


ADV ASSESS

Common Arrhythmias

Sinus Bradycardia

■ ■ ■ ■ ■

Rate: Rhythm: P waves: P-R Interval: QRS:

60/min Regular 1:1 with QRS 0.12–0.2 seconds 0.08–0.12 seconds

Atrial Fibrillation

■ ■ ■ ■

Rate: Rhythm: P waves: QRS:

Page 48

Irregular (R-R interval) Irregular Absent Normal (0.08–0.12 seconds)

48

03White (F)-03

4/6/07

11:18 AM

Page 49


49 Premature Ventricular Contraction (PVC)

■ Rate: ■ Rhythm:

Can be irregular Long pause (compensatory pause) between PVC and next P-QRS complex Absent N/A since P wave is absent with complex Wide ( 0.12 seconds)

■ P waves: ■ P-R Interval: ■ QRS:

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 50


ADV ASSESS Ventricular Tachycardia

■ ■ ■ ■ ■


100–250/min (ventricular rate) Can be irregular Absent during PVC runs N/A (no P waves) Wide ( 0.12 seconds)

Ventricular Fibrillation

■ ■ ■ ■ ■


Irregular and rapid Irregular Absent N/A (no P waves) Absent

50

03White (F)-03

4/6/07

11:18 AM

Page 51


51 1 AV Block

■ ■ ■ ■ ■


Normal Regular Present (1:1 with QRS) Long ( 0.2 seconds) 0.08–0.12 seconds

2 AV Block (Wenckebach or Mobitz type I)

■ ■ ■ ■

Rate: Rhythm: P waves: P-R Interval:

Slow (100) Regular Present Gradual lengthening of P-R interval until it fails to trigger a QRS complex. Then the rhythm repeats itself. Normal (0.08–0.12 seconds)

■ QRS:

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 52


ADV ASSESS 2 AV Block (Mobitz type II)

■ Rate: ■ Rhythm: ■ P waves: ■ P-R Interval: ■ QRS:

Bradycardic (60 /min) Regular Present but they don’t conduct to the ventricles (no QRS) When conduction occurs, normal 0.08–0.12 seconds

3 AV Block

■ Rate: ■ Rhythm: ■ P waves: ■ P-R Interval: ■ QRS:

Atrial and ventricular rates are different (ventricular slower) Atrial and ventricular rhythms are regular Present but they don’t conduct to the ventricles Irregular since the atria and ventricles are paced independently Usually 0.12 seconds

52

03White (F)-03

4/6/07

11:18 AM

Page 53


53 Asystole

■ ■ ■ ■ ■


None None None N/A (no P waves) None

Hemodynamic Monitoring Arterial Pressure Monitoring Noninvasive monitoring can be accomplished using automated sphygmomanometer equipment. Blood pressures can be monitored at set time intervals, with alarm limits and digital displays.

Indwelling Arterial Pressure Lines

Indwelling Arterial Lines

■ Permit continuous real time monitoring of arterial pressures and waveforms. In addition, the lines may be used for arterial blood draws for labs or blood gases. ■ Sites: radial, ulnar, brachial, axillary, or femoral artery. ■ Arterial pressure waveform.

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 54


ADV ASSESS

Central Venous Pressure (CVP) Lines

■ Monitor pressures in the vena cava or right atrium. Right atrial pressures are reflective of blood volume and venous return, which are helpful in evaluating right heart function. ■ Sites: antecubital fossa, basilica, internal jugular, and subclavian veins. ■ Central venous pressure waveform.

54

03White (F)-03

4/6/07

11:18 AM

Page 55


55

Pulmonary Artery Catheter (Swan-Ganz)

■ Monitors pressures in the pulmonary artery and when wedged, left ventricular end diastolic pressure. The line may also be used for cardiac output determination (thermal dilution) and IV infusion. ■ Sites: antecubital fossa, basilica, internal jugular, and subclavian veins. ■ Pulmonary artery pressure waveform.

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 56


ADV ASSESS

Normal Hemodynamic Values Arterial pressures

Venous pressures

Blood pressure

Mean arterial pressure Central venous pressure Right atrial pressure Right ventricular pressure Right ventricular end diastolic pressure

100–140 mmHg systolic, 60–80 mmHg diastolic 80–100 mmHg 6 mmHg CVP 12 mmHg 2–6 mmHg 20–30/0–5 mmHg 2–6 mmHg


56

03White (F)-03

4/6/07

11:18 AM

Page 57


57 Normal Hemodynamic Values (Continued) Pulmonary artery pressures

Pulmonary artery pressure Mean pulmonary artery pressure Pulmonary capillary wedge pressure Left atrial pressure Left ventricular pressure Left ventricular end diastolic pressure

20–30/6–15 mmHg 10–20 mmHg 4–12 mmHg 4–12 mmHg 100–140/0–5 mmHg 5–12 mmHg

Hemodynamic Equations Stroke volume index (SVI) Cardiac index (CI) Right ventricular stroke work index (RVSWI) Left ventricular stroke work index (LVSWI)

SV SVI

BSA Normal: 40–50 mL/beat/m2 CO CI

BSA Normal: 2.5–4 L/min/m2 RVSWI SVI (PA CVP) 0.013 gm/mL Normal 4–12 gm/m/m2 LVSWI SVI (MAP PCWP ) 0.013 gm/mL Normal: 40–75 gm/m/m2

Pulmonary vascular resistance (PVR)

PA PCWP PVR

80 CO Normal: 20–200 dynes·sec·cm5

Systemic vascular resistance (SVR)

MAP CVP SVR

80 CO Normal: 800–1600 dynes·sec·cm5

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Page 58


ADV ASSESS

Basic Hemodynamic Interpretation

Hypovolemia Hypervolemia BP RA PAP PAWP CO

↓ ↓ ↓ ↓ ↓

Right Left Ventricular Ventricular Failure Failure

↑ ↑ ↑ ↑ ↑

↓ ↑ ↑ Normal ↓

↓ Normal ↑ ↑ ↓

Pulmonary Function Testing Static Lung Volumes

Inspiratory reserve volume (IRV) Tidal volume (VT)

Expiratory reserve volume (ERV) Residual volume (RV) *

Definition

Normal*

Maximum volume inhaled after a normal inspiration Amount of air inhaled or exhaled during resting ventilation Maximum amount of air that can be exhaled after a normal exhalation Amount of air left in the lungs following a complete exhalation

3100 mL

Normal values are based on 72 inch male, 21 years old.

58

500 mL

1200 mL

1200 mL

03White (F)-03

4/6/07

11:18 AM

Page 59


59 Static Lung Capacities Normal*

Definition Vital capacity (VC) Inspiratory capacity (IC) Functional residual capacity (FRC) Total lung capacity (TLC) *

ERV VT IRV VT IRV ERV RV

4800 mL 3600 mL 2400 mL

RV ERV VT IRV

6000 mL


Forced Spirometry Normal*

Definition Forced vital capacity (FVC)

Forced expired volume in 1 second (FEV1) FEV1/FVC % Forced expired flow200-1200 (FEF200-1200) Forced expired flow25-75% (FEF25-75%) *

Amount of air that can be exhaled forcefully following a complete inspiration Amount of air exhaled in the first second during an FVC maneuver (FEV1 divided by the FVC)100 Expiratory flow rate between 200 and 1200 mL during the FVC maneuver Expiratory flow during the middle 50% of the FVC maneuver

4800 mL

3600–4080 mL

75–85% 6–7 L/sec

4–5 L/sec


ADV ASSESS

ADV ASSESS

03White (F)-03

60

4/6/07

Page 60


11:18 AM

ADV ASSESS

03White (F)-03

61

4/6/07

Page 61


11:18 AM

Flow Volume Loop


62

Page 62

SB02

ADV ASSESS

03White (F)-03

4/6/07

11:18 AM

Distribution Tests

◆

Single Breath Oxygen Test (Fowler’s Distribution Test) Nitrogen delta (N2 750-1250 mL) 1.5% or less

ADV ASSESS

03White (F)-03

63

4/6/07

Page 63


11:18 AM

Diffusion Tests

Single Breath DLCO

03White (F)-03

4/6/07

11:18 AM

Page 64


ADV ASSESS

■ Single breath diffusion (DLCO) Lung Mechanics ■ Resistance (RAW) ■ Conductance (GAW) ■ Maximal inspiratory pressure (MIP) ■ Maximal expiratory pressure (MEP) ■ Compliance

25–30 mL/min/mmHg 0.6–2.4 cmH2O/L/sec 0.42–1.67 L/sec/cmH2O –60 cmH2O 80 cmH2O 0.1 L/cmH2O

Basic Pulmonary Function Patterns in Disease FVC Asthma

FEV1/ FVC

FEV1

FRC DLCO

RAW

↓ ↑ or normal ↓ ↓

↓

↑

↓

↑

↓

↑

↓

↑

↓

↓

↑

↓

↑

↓ or ↓ or ↓ normal normal ↓ or ↓ or ↓ normal normal

↓

↓ or normal ↓ or normal

Emphysema ↓ Bronchitis Sarcoido- ↓ sis Asbesto- ↓ sis

64

↓

04White (F)-04

4/6/07

11:19 AM

Page 65


65 Oxygen Therapy Oxygen therapy is indicated for documented hypoxemia or when hypoxemia is suspected.

Oxygen Therapy Indications PaO2

SaO2

Other

Acute Care Hospital Adults, children, 60 mmHg breathing infants 28 room air days old

90% breathing room air

50 mmHg breathing room air

88% breathing room air

Infants 28 days old

Severe trauma Acute myocardial infarction Short-term therapy (post anesthesia, etc.) PcO2 40 mmHg (capillary blood gas)

Home or Extended Care Adults, children, infants 28 days old

55 mmHg breathing room air

PROC

56 mmHg PaO2 88% 59 mmHg or breathing SaO2 89% in room air association with cor pulmonale, congestive heart failure, erythrocythemia, etc. SaO2 88% during exercise, sleep, or other activities when SaO2 values do not qualify for oxygen when at rest

PaO2

SpO2

PaO2 55 mmHg while awake on room air at rest PaO2 56 mmHg while awake at rest

SpO2 88 % while awake at rest on room air

Adults

PaO2 56 mmHg while awake at rest on room air

SpO2 89% on room air while awake at rest

Adults

PaO2 55 mmHg during exercise on room air

SpO288% during exercise on room air

Adults

Adults

SpO2 89% on room air while awake at rest

Other

Qualification Continuous O2

PaO2 55 mmHg or SpO2 88% for 5 minutes while sleeping A decrease in PaO2 10 mmHg or decrease in SpO2 5% for 5 minutes while sleeping. With documentation of cor pulmonale, CHF, erythrocytosis, etc. Must document liter flow required to correct hypoxemia

Continuous O2

Continuous O2

O2 during exercise

66


PROC

Page 66 11:19 AM 4/6/07 04White (F)-04

Medicare Home Oxygen Guidelines: Group I (12 months or by physician prescription whichever is less)

04White (F)-04

4/6/07

11:19 AM

Page 67


67 Medicare Home Oxygen Guidelines: Group II (3 months or by physician prescription whichever is less)

Adults

PaO2

SpO2

Other

56–59 mmHg at rest, during sleep (5 minutes), or exercise on room air

89% at rest, during sleep (5 minutes), or exercise on room air

Dependent edema (CHF), pulm hypertension, cor pulmonale, erythrocythemia

Contraindications to Oxygen Therapy No contraindications exist if clinical indications exist.

Oxygen Administration Devices Devices

Liter Flow

Approximate FIO2

Low-Flow Oxygen Devices Nasal cannula Transtracheal catheter Simple oxygen mask Partial rebreathing mask

Non-rebreathing mask

1–6 L/min 0.25–0.5 L/min 6–10 L/min To keep bag open during inspiration (typically 10 L/min). Never run 6 L/min To keep bag open during inspiration (typically 10 L/min)

24–44% 24–44% 35–55% up to 60%

up to 80%

High-Flow Oxygen Devices Venturi or Venti mask

3–15 L/min (per manufacturer for desired FIO2)

PROC

30–50%

04White (F)-04


4/6/07

11:19 AM

Page 68

PROC

Cylinder Duration Cylinder

Contents Contents (cu ft) (liters)

“E”

22 ft3

623 L

Duration Factor Pres. ft3 (28.3 L/ft3) 2200 psi Factor 0.28 L/psi Time (min) Factor (Pressure) Liter Flow

“H” or “K”

3

6905 L

244 ft

Time Pres. ft3 (28.3 L/ft3) 2200 psi Factor 3.14 L/psi Factor (Pres.) Time (min) Liter Flow

Liquid System Duration ■ In the absence of a calibrated scale use the following formula to approximate duration.

Duration (in min)

0.8[(Weight Empty Weight) 343 L/Lb Liquid Oxygen] Liter Flow (L/min)

68

04White (F)-04

4/6/07

11:19 AM

Page 69


69 ■ The factor of 0.8 allows a 20% “fudge factor” prior to exhausting the contents of the reservoir. Empty weight is the weight of the reservoir without any liquid oxygen in it (owners’ or service manual data).

Hazards/Complications of Oxygen Administration ■ Ventilatory depression with PaO2 60 mmHg in patients with chronic hypercarbia (elevated PaCO2) ■ Absorption atelectasis, oxygen toxicity with FIO2 0.50 ■ Retinopathy of prematurity in preterm infants with PaO2 80 mmHg ■ Fire hazard elevated with increased oxygen concentrations ■ Infection hazard increased with application of some humidification devices

PROC

04White (F)-04


4/6/07

11:19 AM

Page 70

PROC

Oxygen Administration Algorithm Oxygen Protocol is Ordered

Contact MD or Provider

Yes

Potential for complications? No

Nasal cannula/ Yes low-flow device to keep SpO2 >92%

Short-term (severe trauma, post-anesthesia), or acute MI? No

Check SpO2 (60 mmHg

Reassess and monitor patient every 24 hours

70

Keep SpO2 88–90% on low-flow delivery system or consider high-flow (Venturi) device

Reassess and monitor patient every 24 hours


Humidity/aerosol therapy is applied to hydrate inspissated retained secretions or to humidify anhydrous medical gases.

Indications for Humidity/Aerosol Therapy

Indication Laryngotracheobronchitis Subglottic edema Postextubation edema Postoperative airway management Artificial airway (bypassed upper airway)

Cool Bland Aerosol

Heated Bland Aerosol

Humidity

Heat Moisture Exchanger (HME)

Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI), Small Volume Nebulizer (SVN)

X

PROC

71

Page 71 11:19 AM 4/6/07 04White (F)-04

Humidity/Aerosol Therapy

X

Heated X humidifier 96 hours or X transport (Text continued on following page)

Indication Sputum induction

Low-flow oxygen 4L/min (nasal cannula, etc.) Administration of pharmacologic agents to the lower respiratory tract

Heated Cool Bland Bland Aerosol Aerosol

Humidity

Metered Dose Inhaler (MDI), Dry Heat Moisture Powder Inhaler Exchanger (DPI), Small Volume (HME) Nebulizer (SVN)

X (Hypertonic saline) X Bubble humidifier

72


PROC

Page 72 11:19 AM 4/6/07 04White (F)-04

Indications for Humidity/Aerosol Therapy (Continued)

X

04White (F)-04

4/6/07

11:19 AM

Page 73


73 Contraindications for Humidity/Aerosol Therapy ■ Bronchoconstriction ■ Airway hypersensitivity ■ Specific contraindications to pharmacologic agents (see package insert) ■ HME contraindications: ■ Thick copious or bloody secretions ■ Exhaled volumes 70% delivered (bronchopulmonary fistula, cuff leak) ■ Hypothermia (32 degrees Celsius) ■ High minute volumes (10 L/min)

Types of Humidifiers/Nebulizers and Their Application Device Room humidifier Aerosol tent

Bubble humidifier

Heated humidifier with alarms

Application

Liter Flow/Setting

Increase relative humidity of a room

Fill reservoir, connect to electrical outlet and turn unit on Pediatrics (laryngotra- Fill reservoir, maximum cheobronchitis, flow to achieve a epiglottitis, etc.) dense mist, titrate FIO2 to maintain SpO2 92% Low-flow oxygen Set liter flow delivery (nasal to achieve cannula, simple SpO2 90 % mask, etc.) Mechanical 31–35 degrees Celsius ventilation, bilevel at the airway or set positive airway for a neutral thermal pressure, CPAP, artienvironment (infant ficial airway, infant application) hood or headbox for neutral thermal environment (Text continued on following page)

PROC

04White (F)-04


4/6/07

11:19 AM

Page 74

PROC

Types of Humidifiers/Nebulizers and Their Application (Continued) Device Heat and moisture exchanger (HME)

Application Artificial airway with short-term mechanical ventilation (96 hours)

Delivery of pharmacologic agents to the lower respiratory tract Delivery of Respiguard SVN pentamidine Delivery of Metered dose pharmacologic inhalers (MDI), agents to the dry powder lower respirainhalers (DPI) tory tract Administration of Large volume bland aerosol nebulizer (cool or heated) HEART (continuous) Continuous administration of nebulizer bronchodilator Small volume nebulizer (SVN)

Ultrasonic nebulizer Administration of bland aerosol

74

Liter Flow/Setting Monitor for increased airway resistance (airway pressures, use of accessory muscles, etc.) 6–8 L/min

6–8 L/min Use holding chamber (MDI)

Titrate liter flow and FIO2 to maintain SpO2 90% Set liter flow per manufacturer for desired mg/hr delivery Fill reservoir, set output control for a dense aerosol, use caution with asthmatic patients


Yes

No

Medication delivery?

No

Yes

Secretion hydration? Yes

HME if duration is less than 96 hours

SVN, MDI, or DPI

Large volume nebulizer

Heated humidifier with temperature display and alarms

If patient requires continuous bronchodilator therapy, us a HEART continuous nebulizer

Ultrasonic nebulizer (contraindicated with bronchospasm/ asthma)

Nasal cannula >4 L/min? Yes Bubble humidifier

No

Subglottic edema?

No

Yes Adults: cool aerosol via large volume nebulizer

Pediatrics: mist tent

PROC

Artificial airway?

75

Page 75 11:19 AM 4/6/07 04White (F)-04

Humidity/Aerosol Therapy Algorithm

04White (F)-04


4/6/07

11:19 AM

Page 76

PROC

Hazards/Complications of Humidity and Aerosol Therapy ■ Humidity Therapy ■ Electrical shock (heated humidifiers) ■ Hypothermia (HME devices) ■ Thermal injury (heated humidifiers) ■ Swelling of inspissated secretions (heated or cool humidity) ■ Increased airway resistance (HME devices) ■ Infection ■ Aerosol Therapy ■ Bronchospasm ■ Infection ■ Overhydration ■ Airway edema ■ Exposure of caregivers to secondhand aerosol

Hyperinflation Therapy Hyperinflation therapy is used to achieve lung expansion to reverse or prevent atelectasis, to mobilize secretions, to promote effective coughing, and to improve delivery of medications.

Indications for Hyperinflation Therapy ■ Atelectasis, predisposition for atelectasis (upper abdominal or thoracic surgery) ■ Restrictive lung defect (neuromuscular) ■ Inability to clear secretions ■ Reduce air trapping in chronic obstructive pulmonary disease ■ Optimize delivery of bronchodilators

Contraindications to Hyperinflation Therapy ■ Incentive spirometry ■ Patient cannot be instructed or supervised ■ Patient is uncooperative or cannot understand instructions ■ Patient unable to deep breathe (VC 10 mL/kg)

76

04White (F)-04

4/6/07

11:19 AM

Page 77


77 ■ PEP/oscillating PEP therapy/CPAP/bilevel positive airway pressure ■ Patient unable to tolerate increased work of breathing ■ Increased intracranial pressure ■ Cardiovascular compromise (myocardial ischemia, decreased venous return) ■ Gastric distension or risk of vomiting ■ Claustrophobia ■ Facial skin breakdown from use of a mask ■ Pulmonary barotraumas ■ Intermittent positive pressure breathing (IPPB) ■ Absolute contraindication: Untreated pneumothorax ■ Intracranial pressure 15 mmHg ■ Hemodynamic instability ■ Recent facial, oral, sinus, or skull surgery ■ Tracheoesophageal fistula ■ Recent esophageal surgery ■ Hemoptysis ■ Nausea/vomiting/gastric distension ■ Active untreated tuberculosis ■ Evidence of blebs on chest x-ray

Hyperinflation Techniques Technique

Indications

Clinical Goal

Comments

Atelectasis, Some patients Increase Incentive predisposition transairway may lack spirometry for atelectasis, ventilatory pressure or neuromusmuscle improving cular restricstrength to lung tive lung perform volumes defect therapy. Patient can perform technique independently. (Text continued on following page)

PROC

04White (F)-04

4/6/07


11:19 AM

Page 78

PROC

Hyperinflation Techniques (Continued) Technique

Indications

Clinical Goal

Positive ex- Atelectasis, re- Splint airways piratory tained secreopen during pressure tions, air exhalation, (PEP) trapping improving associated distribution with COPD and ability to mobilize secretions (↑ FRC)

Oscillating PEP therapy

Atelectasis, retained secretions, air trapping associated with COPD

Comments Patient must be able to cooperate (spontaneously breathing). Can be combined with SVN for simultaneous medication delivery. Patient can perform technique independently.

Splint airways Patient must be able to coopopen during erate (spontaexhalation neously with oscillating pressure. breathing). Can be combined Improve diswith SVN for tribution of simultaneous ventilation and mobilize medication delivery. Patient secretions can perform (↑ FRC) technique independently. (Text continued on following page)

78

04White (F)-04

4/6/07

11:19 AM

Page 79


79 Hyperinflation Techniques (Continued) Technique

Indications

Clinical Goal

Comments

Intermittent Pulmonary Application of Application positive atelectasis positive presof positive pressure (following sure during pressure during breathing failure of inspiration inspiration to (IPPB) other techto hyperhyperinflate the niques), inflate the lungs while mobilize lungs while simultaneously secretions, simultanedelivering a deliver ously delivmedication medications, ering a short-term medication ventilatory support Continuous Application Increase FRC Increase FRC and positive of positive and hyperhyperinflate the airway pressure inflate the lungs pressure (10–20 cm lungs (CPAP) H2O) during inhalation and exhalation Bilevel Application of Increase FRC Increase FRC and positive inspiratory and hyperhyperinflate the airway and inflate the lungs pressure expiratory lungs positive airway pressure

PROC

04White (F)-04

4/6/07


11:19 AM

Page 80

PROC

Hyperinflation Algorithm Hyperinflation Therapy Protocol is Ordered

Contact MD or Provider

Yes Contraindications? No

Incentive spirometry, PEP therapy

Yes

Patient’s VC >10 mL/kg and able to follow directions? No Consider IPPB therapy (volume oriented) to 25%> spontaneous volume

Evaluate goals: Improved breath sounds? Resolving atelectasis? Improved vital signs? Improved VC? Improved SpO2 or PaO2?

Consider CPAP therapy via mask intermittently

Continue or modify therapy

Consider intermittent application of bilevel positive airway pressure via mask

Evaluate goals: Improved breath sounds? Resolving atelectasis? Improved vital signs? Improved VC? Improved SpO2 or PaO2?

Continue or modify therapy

80

04White (F)-04

4/6/07

11:19 AM

Page 81


81 Hazards/Complications of Hyperinflation Therapy ■ Hyperventilation (hypocarbia) ■ Barotrauma (positive pressure techniques) ■ Hypoxemia (if supplemental oxygen is removed for extended period during therapy) ■ Increased intracranial pressures (positive pressure techniques) ■ Cardiovascular compromise (positive pressure techniques) ■ Gastric insufflation (positive pressure techniques)

Bronchial Hygiene Bronchial hygiene techniques are used to improve coughing and facilitate mobilization of secretions. Many of these techniques overlap some of the hyperinflation therapy techniques.

Indications for Bronchial Hygiene ■ Presence of or predisposition for atelectasis ■ Retained secretions or inability to effectively mobilize secretions ■ Evidence of cystic fibrosis, bronchiectasis, or cavitating lung disease ■ Difficulty clearing secretions with sputum production 25–30 mL/day (adult) ■ Evidence of retained secretions with the presence of an artificial airway

Contraindications to Bronchial Hygiene Therapy ■ PEP/Flutter valve therapy/CPAP/bilevel positive airway pressure ■ Patient unable to tolerate increased work of breathing ■ Increased intracranial pressure ■ Cardiovascular compromise (myocardial ischemia, decreased venous return)

PROC

04White (F)-04


4/6/07

11:19 AM

PROC

■ Gastric distension or risk of vomiting ■ Claustrophobia ■ Facial skin breakdown from use of a mask ■ Pulmonary barotraumas ■ Chest physiotherapy and postural drainage (CPPD) ■ Patient positioning ■ Absolute contraindications ◆ Unstable cervical fractures ◆ Hemorrhage with hemodynamic instability ■ Relative contraindications ◆ Increased intracranial pressure (20 mmHg) ◆ Recent spinal surgery ◆ Acute spinal injury ◆ Untreated empyema ◆ Bronchopulmonary fistula ◆ Pulmonary edema associated with congestive heart failure ◆ Pleural effusion ◆ Patient unable to tolerate positional changes ◆ Rib fractures ◆ Uncontrolled hypertension ◆ Frank uncontrolled hemoptysis ◆ Aspiration risk ■ External chest wall manipulation ■ Subcutaneous emphysema ■ Recent epidural or spinal anesthesia ■ Recent skin grafts ■ Burns, open wounds, or skin infections ■ Recent pacemaker implantation ■ Suspected pulmonary tuberculosis ■ Lung contusion ■ Osteomyelitis of the ribs ■ Osteoporosis ■ Coagulopathy ■ Complaint of chest wall pain

82

Page 82

04White (F)-04

4/6/07

11:19 AM

Page 83


83 Bronchial Hygiene Techniques Technique Positive expiratory pressure (PEP)

Oscillating PEP therapy

Chest physiotherapy and postural drainage (CPPD)

Indications

Clinical Goals

Comments

Patient must be able to cooperate (spontaneously breathing). Can be combined with SVN for simultaneous medication delivery. Patient can perform technique independently. Atelectasis, Splint airways Patient must be able to retained open during cooperate secretions, exhalation (spontaneously air trapping with oscillatbreathing). Can associated ing pressure. be combined with COPD Improve with SVN for distribution simultaneous of ventilamedication tion and delivery. Patient mobilize can perform secretions technique (↑ FRC) independently. Clinical efficacy is Atelectasis, Patient posilargely based retained tioning to upon anecdotal secretions, facilitate evidence. problems pulmonary clearing drainage secretions with external chest wall manipulation Atelectasis, Splint airways retained open during secretions, exhalation air trapping improving associated distribution with COPD and ability to mobilize secretions (FRC)


PROC

04White (F)-04


4/6/07

11:19 AM

Page 84

PROC

Bronchial Hygiene Techniques (Continued) Technique

Indications

Clinical Goals

Comments

High-frequency Secretions, External manip- Patient may problems ulation of the perform chest wall clearing chest wall therapy indeoscillation 7 secretions using highpendently. (The Vest ) frequency Equipment is pressure expensive. pulses through a pneumatic vest worn by the patient Can be used for Intrapulmonary Secretions, Use of a highproblems frequency simultaneous percussive clearing ventilator to medication ventilation secretions increase delivery. (IPV) mean airway Patient may pressures be instructed while mobito perform lizing secretherapy indetions with pendently. pressure pulses

84

04White (F)-04

4/6/07

11:19 AM

Page 85


85 Postural Drainage Positions

Posterior Apical Segments of the Right and Left Upper Lobes

■ Position the patient sitting and leaning forward at about a 45-degree angle ■ Area for percussion is just above the scapula with the fingers extending up onto the shoulders

Anterior Apical Segments of the Right and Left Upper Lobes

■ Position the patient sitting and leaning back at about a 45-degree angle ■ Area for percussion is just below the clavicle

Anterior Segments of the Right and Left Upper Lobes

■ Position the patient supine with the bed flat ■ Area for percussion is just above the nipple

PROC

04White (F)-04


4/6/07

11:19 AM

Page 86

PROC

Posterior Segment of the Left Upper Lobe

■ Position the patient 1/4 turn from prone and resting on the right side with the head of the bed elevated 18 inches ■ Area for percussion is just over the left scapula

Posterior Segment of the Right Upper Lobe

■ Position the patient 1/4 turn from prone and resting on the left side with the bed flat ■ Area for percussion is just over the right scapula

Left Lingula

■ Position the patient 1/4 turn from supine and resting on the right side with the foot of the bed elevated 12 inches ■ Area to percuss is just above the left nipple and under the armpit

86

04White (F)-04

4/6/07

11:19 AM

Page 87


87 Right Middle Lobe

■ Position the patient 1/4 turn from supine with the foot of the bed elevated 12 inches ■ Area to percuss is just above the right nipple and under the armpit

Anterior Basal Segments of the Right and Left Lung

■ Position the patient supine with the foot of the bed elevated 18 to 20 inches ■ Area to percuss is over the lower ribs

Posterior Basal Segments of the Right and Left Lung

■ Position the patient prone with the foot of the bed elevated 18 to 20 inches ■ Area to percuss is over the lower ribs

PROC

04White (F)-04


4/6/07

11:19 AM

Page 88

PROC

Left Lateral Segment of the Lower Lobes

■ Position the patient on the right side with the foot of the bed elevated 18 to 20 inches ■ Area to percuss is over the lower ribs

Right Lateral Segment of the Lower Lobes

■ Position the patient on the left side with the foot of the bed elevated 18 to 20 inches ■ Area to percuss is over the lower ribs

Superior Segments of the Right and Left Lower Lobes

■ Position the patient prone and with the bed flat ■ Area to percuss is over just below the lower margin of the scapula

88

04White (F)-04

4/6/07

11:19 AM

Page 89


89 Bronchial Hygiene Care Plan Bronchial Hygiene Protocol is Ordered

Consult MD or Provider

Yes Contraindications? No Assess patient, are indications present: Sputum prod >25 mL/day? Decreased or absent breath sounds? Atelectasis on chest x-ray? Tachypnea or tachycardia? Abnormal ABGs?

Select mode/technique: PEP therapy? Flutter valve? CPPD? HFCWO? IPV?

Reevaluate patient after 24 hours

Assess outcomes: Sputum prod 1 year: Check rhythm. Shockable rhythm?

9

Shockable

Give 1 shock Resume CPR immediately for 5 cycles

Not shockable

10

Resume CPR immediately for 5 cycles Check rhythm every 5 cycles; continue until ALS providers take over or victim starts to move

Note that boxes bordered by dotted lines are performed by health-care providers and not by lay rescuers. (From: 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005 112 [Suppl I]: IV-158, © 2005 American Heart Association, with permission.)

CRIT CARE

05White (F)-05

4/6/07


5:18 PM

Page 154

CRIT CARE

Child Foreign Body Airway Obstruction No

Yes Are there signs of severe airway obstruction? Yes

Monitor the victim No Ask: Are you choking? Yes Perform abdominal thrusts to remove foreign body

No

Is the victim unconscious or unresponsive? Yes 1. Activate EMS System 2. Initiate CPR 3. When opening the airway, if object is observed, remove it

154

05White (F)-05

4/6/07

5:18 PM

Page 155


155 One-Man Infant CPR Assess Responsiveness Victim is unresponsive Activate EMS Place victim in recovery position and observe victim

Victim is Breathing

Assess Breathing Victim is Not Breathing Open the airway: 1. Head tilt-chin lift 2. Jaw-thrust

Perform rescue breathing: 2 slow breaths (1 second per breath)

Continue rescue breathing, 1 breath every 3–5 seconds

No

Check pulse < 60/min (brachial or femoral) Yes

Begin chest compressions: 30 compression (100 per minute) to 2 rescue breaths

After 5 cycles, reassess the patient 1. Resume CPR or 2. Provide rescue breathing or 3. Place patient in recovery position

CRIT CARE

05White (F)-05

4/6/07

5:18 PM


Page 156

CRIT CARE

Two-Man Infant CPR Assess Responsiveness Victim is Unresponsive Activate EMS Place victim in recovery position and observe victim

Victim is Breathing

Assess Breathing Victim is Not Breathing Open the airway: 1. Head tilt-chin lift 2. Jaw-thrust

Perform rescue breathing: 2 slow breaths (1 second per breath)

Continue rescue breathing, 1 breath every 3–5 seconds

No

Check pulse < 60/min (brachial or femoral) Yes

Begin chest compressions: 15 compression (100 per minute) to 2 rescue breaths

After 5 cycles, reassess the patient 1. Resume CPR or 2. Provide rescue breathing or 3. Place patient in recovery position

156

05White (F)-05

4/6/07

5:18 PM

Page 157


157 Infant Foreign Body Airway Obstruction

Monitor the victim

No

Are there signs of severe airway obstruction? Yes Perform back slaps and abdominal thrusts to remove foreign body

Is the victim unconscious or unresponsive? Yes 1. Activate EMS System 2. Initiate CPR 3. When opening the airway, if object is observed, remove it

CRIT CARE

05White (F)-05

4/6/07


5:18 PM

Page 158

CRIT CARE

Automated External Defibrillator (AED) Algorithm No Monitor the victim

Is the victim unresponsive? Yes Airway and Breathing 1. Check breathing 2. Open airway 3. Give 2 rescue breaths

Circulation: 1. Check pulse 2. Begin compressions 30:2

Automated External Defibrillator 1. Place AED next to victim, turn on power 2. Attach pads at sternum and apex 3. Clear victim and press “ANALYZE” 4. Clear victim and “SHOCK” if advised 5. Don't touch victim and “ANALYZE” 6. Check carotid pulse and continue CPR if indicated

Monitor the patient for: 1. Breathing 2. Pulse and circulation

158

05White (F)-05

4/6/07

5:18 PM


159 Notes

CRIT CARE

Page 159

05White (F)-05

4/6/07


5:18 PM

Page 160

CRIT CARE

Advanced Cardiac Life Support Pulseless Arrest Algorithm PULSELESS ARREST

1

• BLS Algorithm: Call for help; give CPR • Give oxygen when available • Attach monitor/defibrillator when available Not shockable

Shockable

3

VF/VT

2

Check rhythm Shockable rhythm?

9

Asystole/PEA

4 10

Give 1 shock • Manual biphasic: device specific (typically 120 to 200 J) Note: If unknown, use 200J • AED: device specific • Monophasic: 360 J Resume CPR immediately Give 5 cycle of CPR*

5

Check rhythm Shockable rhythm?

No

Resume CPR immediately for 5 cycles When IV/IO available, give vasopessor • Epinephrine 1 mg IV/IO Repeat every 3 to 5 min or • May give 1 dose or vasopressin 40 U IV/IO to replace first or second dose of epinephrine Consider atropine 1 mg /IV/IO for asystole or slow PEA rate Repeat every 3 to 5 min (up to 3 doses)

Text/image rights not available. 6

Shockable

Continue CPR while defibrillator is charging Give 1 shock • Manual biphasic: device specific (same as first shock or higher) Note: If unknown, use 200J • AED: device specific • Monophasic: 360 J Resume CPR immediately after the shock When IV/IO available, give vasopressor during CPR (before or after the shock) • Epinephrine 1 mg IV/IO Repeat every 3 to 5 min or • May give 1 dose of vasopressin 40 U IV/IO to replace first or second dose of epinephrine

Give 5 cycle of CPR*

11 Check rhythm Shockable rhythm?

Not shockable

Give 5 cycle of CPR*

160

Shockable

05White (F)-05

4/6/07

5:18 PM

Page 161


161 7

12 Check rhythm Shockable rhythm?

Shockable

No

13

• If asystole, go to Box 10 • If electrical activity, check pulse. If no pulse go to Box 10 • If pulse present, begin postresuscitation care

Go to Box 4

8 Continue CPR while defibrillator is charging Give 1 shock • Manual biphasic: device specific (same as first shock or higher dose) Note: If unknown, use 200J • AED: device specific • Monophasic: 360 J Resume CPR immediately after the shock Consider antiarrhythmics; give during CPR (before and after the shock) amiodarone (300 mg IV/IO once, then consider additional 150 mg IV/IO once) or lidocaine (1 to 1.5 mg/kg first dose, then 0.5 to 0.75 mg/kg IV/IO, maximum 3 doses or 3 mg/kg) Consider magnesium, loading dose 1 to 2 g IV/IO for torsades de pointes After 5 cycle of CPR,* go to Box 5 above

Text/image rights not available. During CPR • Push hard and fast (100/min) • Ensure full chest recoil • Minimize interruptions in chest compressions • One cycle of CPR: 30 compressions then 2 breaths; 5 cycles = 2 min • Avoid hyperventilation • Secure airway and confirm placement • Rotate compressors every 2 min with rhythm checks • Search for and treat possible contributing factors:

– Hypovolemia – Hypoxia – Hydrogen ion (acidosis) – Hypo-/hyperkalemia – Hypoglycemia – Hypothermia – Toxins – Tamponade, cardiac – Tension pneumothorax – Thrombosis (coronary or pulmonary) – Trauma

* After an advance airway is placed rescuers no longer deliver “cycles” of CPR. Give continuous chest compressions without pauses for breaths. Give 8 to 10 breaths/minute. Check rhythm every 2 miniutes.

(From: 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005 112 [Suppl I]: IV-59, © 2005 American Heart Association, with permission.)

CRIT CARE

05White (F)-05

4/6/07

5:18 PM


Page 162

CRIT CARE

Bradycardia Algorithm

1 • • • •

BRADYCARDIA Heart rate 220 min) • Child (Rate >180 min)

Ventricular Tachycardia? • Cardiovert (0.5–1 J/kg)

Perform vagal maneuvers

192

06White (F)-06

4/6/07

5:58 PM

Page 193


193

Immediate cardioversion OR Immediate IV/IO w/adenosine: • Adenosine (0.1 mg/kg • Cardiovert (0.5–1 J/kg IV/IO [max dose 6 mg]) can to 2 J/kg) • May double and repeat • Sedate if possible once up to 12 mg • Sedation must not (use rapid bolus) delay cardioversion

Consider: • Amiodarone (5 mg/kg IV over 20–60 min) • Procainamide (15 mg/kg IV over 30–60 min). Don’t give amiodarone and procainamide together OR • Lidocaine (1 mg/kg IV bolus [wide complex only]) • Repeat 12-lead ECG

NEO PEDS

Page 194

Generic Name (Trade Name)

Availability

Strength (Dosage)

Side Effects

albuterol sulfate (Proventil, Ventolin)

1. Metered dose inhaler (MDI) 2. Inhalant solution 3. Syrup 4. Tablet

1. 90 mcg/puff (2 puffs 4 daily) 2. 0.5% or 5mg/mL (2.5 mg 4 daily) 3. 2mg/5mL (0.4mg/mL) (2–4 mg 3 or 4 daily) 4. 2 or 4 mg (2 or 4 mg 3 or 4 daily)

Tremors, tachycardia, palpitations, nausea, nervousness, dizziness, tachyphylaxis, headache

bitolterol (Tornalate)

MDI

0.37 mcg/puff (2 puffs every 8 hr)

Same as for albuterol

epinephrine (Adrenalin)

Inhalant solution

1% or 10 mg/mL (2.5–5 mg 4 daily)


formoterol fumarate (Foradil)

Dry powder inhaler (DPI)

12 mcg/puff (1 puff 2 daily)


isoetharine HCl (Bronkosol, Bronkometer)

1. Inhalant solution 2. MDI

1. 1% or 10 mg/mL (2.5– 5 mg 4 daily) 2. 340 mcg/puff (1–2 puffs 4 daily)



194

PHARM

Sympathomimetic Agents


6:24 PM 4/6/07 07White (F)-07

Bronchodilators


195

Availability

Strength (Dosage)

Side Effects

levalbuterol (Xopenex)

1. Inhalant solution 1. 0.31, 0.63 and 1.25 mg 2. MDI (1.25 mg every 6–8 hr) 2. 45 mcg/puff (2 puffs every 4–6 hr)

metaproterenol sulfate (Alupent, Metaprel)

1. 2. 3. 4.

pirbuterol (Maxair)

MDI

0.2 mcg/puff (2 puffs every 4–6 hr)


racemic epinephrine (Micronefrin, Vaponefrin)

Inhalant solution

2.25% or 22.5 mg/mL (5.625–11.25 mg 4 daily)



MDI 1. 0.65 mcg/puff Same as for Inhalant solution (2–3 puffs every 4 hr) albuterol Syrup 2. 5% or 50 mg/mL Tablet (5, 10, or 15 mg 3 or 4 daily) 3. 2 mg/mL (10 mg 3 or 4 daily) 4. 10 and 20 mg (20 mg 3 or 4 daily)


PHARM

Page 195 6:24 PM 4/6/07 07White (F)-07

Sympathomimetic Agents (Continued) Generic Name (Trade Name)

Availability

Strength (Dosage)

salmeterol (Serevent)

DPI

50 mcg/puff (1 puff 2 daily)

terbutaline (Brethaire, Brethine, Bricanyl)

1. MDI 2. DPI

1. 25 mcg/puff (2 puffs every 8 hr) 2. 50 mcg/puff (2 daily)

Side Effects Same as for albuterol Same as for albuterol

196

PHARM Copyright © 2008 by F. A. Davis.

Page 196 6:24 PM 4/6/07 07White (F)-07

Sympathomimetic Agents (Continued) Generic Name (Trade Name)

Anticholinergic Agents Generic Name (Trade Name) atropine sulfate (Atropine)

Availability Inhalant solution

Strength (Dosage) 0.2% or 2 mg/mL (0.025 mg/kg 3 or 4 daily)

Side Effects Dry mouth, dysphagia, dysphonia


197


Availability

Strength (Dosage)

Side Effects

Ipratropium bromide (Atrovent)

1. Inhalant solution 2. Metered dose inhaler (MDI)

1. 0.5 mg or 500 mcg (unit dose) up to 4 daily 2. 18 mcg/puff (2 puffs 4 daily)

Same as for atropine

ipratropium bromide AND albuterol sulfate (DuoNeb, Combivent)

1. Inhalant solution 2. MDI

1. 0.083% or 3 mg Albuterol and 0.017% or 0.5 mg Atrovent (1 unit dose 4 daily) 2. 103 mcg/puff Albuterol and 18 mcg/puff Atrovent

Same as for atropine. Also dizziness, headache, nausea, nervousness, palpitations, tachycardia, tachyphylaxis, tremors

tiotropium bromide (Spiriva)

Dry powder inhaler (DPI)

18 mcg/capsule (1 capsule once daily)

Same as for atropine

PHARM


Page 197 6:24 PM 4/6/07 07White (F)-07

Anticholinergic Agents (Continued)


Availability

Strength (Dosage)

aminophylline (Aminophylline 100, Aminophylline 360)

1. Tablets 2. Elixir 3. Suppository

1. 100 mg (10–12 mcg/dL serum level) 2. 21 mg/mL (10–12 mcg/dL serum level) 3. 360 mg (10–12 mcg/dL serum level)

Headache, anxiety, restlessness, tremor, convulsions, nausea, vomiting, abdominal pain, diarrhea, tachypnea, palpitations, diuresis

Side Effects

theophylline (Aerolate, SloPhyllin, Theolair, Theo-Dur)

1. Capsules/ tablets 2. Elixir

1. 200 mg, 260 mg, 300 mg and 400 mg (10–12 mcg/dL serum level) 2. 10 mg/mL (10–12 mcg/dL serum level)

Headache, anxiety, restlessness, tremor, convulsions, nausea, vomiting, abdominal pain, diarrhea, tachypnea, palpitations, diuresis

198


07White (F)-07

4/6/07

6:24 PM

Page 198

Xanthine


beclomethasone dipropionate (Beclovent, Vanceril) beclomethasone dipropionate HFA (QVAR) budesonide (Pulmicort)

Availability

Strength (Dosage)

Metered dose 42 mcg/puff (2 puffs 3 or 4 inhaler (MDI) daily)

MDI

1. Dry powder inhaler (DPI) 2. Inhalant solution

flunisolide (AeroBid) MDI flunisolide 1. MDI (Flovent) 2. DPI triamcinolone aceto- MDI nide (Azmacort)

PHARM

Pulmonary Inhaled Corticosteroids Generic Name (Trade Name)

199

Page 199 6:24 PM 4/6/07 07White (F)-07

Corticosteroids

Side Effects

Oropharyngeal fungal infections, dysphonia, dysphagia, cough, bronchoconstriction Oropharyngeal fungal 40 mcg and 80 mcg/puff (1–2 infections, dysphonia, puffs 2 daily) dysphagia 1. 200 mcg/cycle (1–2 2 daily) Oropharyngeal fungal infections, dysphonia, 2. 0.25 mg/mL (0.5 mg once daily) dysphagia, cough, bronchoconstriction Same as for budesonide 250 mcg/puff (2 puffs 2 daily) Same as for budesonide 1. 44, 110, or 220 mcg/ puff (2 puffs 2 daily) 2. 50, 100, or 250 mcg/puff Same as for budesonide 100 mcg/puff (2 puffs 3 or 4 daily)

Generic Name (Trade Name) fluticasone propionate and salmeterol (Flovent and Serevent)

Availability Dry powder inhaler (DPI)

Strength (Dosage) 100/50, 250/50 and 500/50 mcg/puff Flovent/Serevent (1 puff 2 daily)

Side Effects Bronchoconstriction, cough, dizziness, dysphonia, dysphagia, headache, nervousness, oropharyngeal fungal infections, palpitations

Nasal Inhaled Corticosteroids Generic Name (Trade Name) beclomethasone (Beconase, Vancenase) budesonide (Rhinocort) flunisolide (Nasalide) fluticasone (Flonase)

Availability Metered dose inhaler (MDI) MDI MDI MDI

Strength (Dosage)

200


Page 200 6:24 PM 4/6/07 07White (F)-07

Pulmonary Combination Product

Side Effects

42 mcg/spray (1 inhalation Contact dermatitis, wheezing, per nostril 2–4 daily) nasal septum irritation, ↑ intraocular pressure 32 mcg/spray (2 sprays Same as for beclomethasone each nostril 2 daily) 29 mcg/spray (2 sprays Same as for beclomethasone each nostril 2 daily) 32 mcg/spray (2 sprays Same as for beclomethasone each nostril 2 daily)


Availability

mometasone (Nasonex) triamcinolone acetonide (Nasacort)

MDI MDI

Strength (Dosage) 50 mcg/spray (2 sprays each nostril once daily) 55 mcg/spray (2 sprays each nostril 2 daily)

Side Effects Same as for beclomethasone Same as for beclomethasone

07White (F)-07

201

4/6/07

Nonsteroidal Asthma Medications Generic Name (Trade Name) cromolyn sodium (Intal)

montelukast (Singulair)

Availability 1. Metered dose inhaler (MDI) 2. Inhalant solution 3. Dry powder inhaler (DPI) Tablet

Strength (Dosage) 1. 800 mcg/puff (2 puffs 4 daily) 2. 20 mg/unit dose (1 unit dose 4 daily) 3. 20 mg capsule (1 dose 4 daily) 10 mg (1 tablet daily)

Side Effects Nasal congestion, dermatitis, cough, wheezing, epistaxis

Diarrhea, laryngitis, pharyngitis, nausea, sinusitis (Text continued on following page)

PHARM


Page 201 6:24 PM

Nasal Inhaled Corticosteroids (Continued)


Availability

Strength (Dosage)

Side Effects Pain, fatigue, musculoskeletal pain, dizziness, dermatitis

Tablet

75 mg and 150 mg vials (150–375 mg injected subcutaneously every 2–4 weeks) 20 mg (1 tablet 2 daily)

Tablet

600 mg (1 tablet 4 daily)

omalizumab (Xolair)

Injection solution

zafirlukast (Accolate) zileuton (Zyflo)

Headache, infection, nausea, diarrhea, abdominal pain Headache, pain, abdominal pain, lethargy, elevated liver enzymes

Mucous Agents Generic Name (Trade Name) dornase Alfa (Pulmozyme) guaifenesin (Mucinex)

Availability

Strength (Dosage)

Inhalant solution Tablet

1mg/mL (2.5 mg once daily) 600 mg (1–2 tablets every 12 hr)

Side Effects Dysphonia, pharyngitis, laryngitis, rash, cough, chest pain Nausea, cardiac palpitations, nervousness, headache, dizziness, tachycardia, diarrhea (Text continued on following page)

202


Page 202 6:24 PM 4/6/07 07White (F)-07

Nonsteroidal Asthma Medications (Continued)



sodium bicarbonate

Inhalant solution

203

N-acetylcysteine (Mucomyst)

Strength (Dosage) 10% and 20% solution or 100 and 200 mg/mL (3–5 mL [20%] or 6–10 mL [10%] nebulized 3 or 4 daily) 2% or 20 mg/mL (2–5 mL up to 4 daily)

Side Effects Bronchospasm, nausea, rhinorrhea, airway obstruction Bronchial irritation

Surfactant Agents Generic Name (Trade Name) beractant (Survanta)


Strength (Dosage)

Side Effects

25 mg/mL (100 mg/kg Pulmonary compliance birth weight instilled (barotraumas), airway endotracheally) occlusion, high PaO2 values, overventilation, apnea, pulmonary hemorrhage colfosceril palmitate Powder Same as for beractant 13.5 mg/mL (5 mL/kg (Exosurf) (reconstituted birth weight instilled in sterile water) endotracheally)

PHARM


Page 203 6:24 PM 4/6/07 07White (F)-07

Mucous Agents (Continued)


Availability

Strength (Dosage)

Side Effects

pentamidine isethionate (Pentamidine)

Dry powder reconstituted in sterile water as an inhalant solution

300 mg (300 mg once every 4 wk)

Cough, bronchial irritation, dyspnea, bronchospasm

ribavirin (Virazole)

Dry powder (6 gm) reconstituted in 30 mL of sterile water for an inhalant solution

20 mg/mL (inhaled for 12–18 hr/day for 3 days minimum using a SPAG nebulizer)

Bronchospasm, hypotension, rash, conjunctivitis

tobramycin (Tobi)

Inhalant solution

300 mg unit dose (1 unit dose 2 daily for 28 days. Dosing should be followed by 28 days off the medication)

Cough, pharyngitis, rhinitis, dyspnea, fever, headache, chest pain, hemoptysis, bronchospasm

zanamivir (Relenza)

Dry powder inhaler

5 mg/dose blisters (2 inhalations 2 daily for 5 days)

Diarrhea, nausea, vomiting, bronchitis, cough, dizziness

204


Page 204 6:24 PM 4/6/07 07White (F)-07

Inhaled Antimicrobial Agents


Availability

PHARM

Cardiac Glycosides Generic Name (Trade Name)

Strength (Dosage)

Side Effects

digoxin (Lanoxin)

Capsules

50, 100, 150, 200 mcg (1.2–1.6 mg initial then 0.05–0.3 mg daily)

digitoxin (Purodigin)

Capsules, IV solution

50, 100, 200 mcg, 100 and 250 mcg/mL Inj solution (0.5 mg over 5 min then 0.125–0.5 mg daily as needed)

205

Page 205 6:24 PM 4/6/07 07White (F)-07

Cardiac Pharmacology

CHF symptoms, arrhythmias, hypotension Same as for digoxin

Antiarrhythmic Agents Generic Name (Trade Name)

Availability

Strength (Dosage)

Side Effects

1. Capsules

1. 100 and 150 mg (300 mg initial then 150 mg every 6 hr)

1. Dry mouth, urinary retention

Class IA 1. disopyramide (Norpace)



Availability

Strength (Dosage)

Side Effects

Class IA 2. procainamide (Procanbid)

2. Tablets

2. 500 mg (50 mg/kg daily)

3. quinidine (Quinaglute)

3. Tablets

3. 324 mg (2 tablets every 8 hr)

1. lidocaine (Xylocaine)

1. IV

1. 4%, 10%, 20% (1 mg/kg)

2. mexilentine (Mexitil)

2. Capsules

2. 150, 200, and 250 mg (400 mg initial then 200 mg in 8 hr)

3. tocainide (Tonocard)

3. Tablets

3. 400 mg (400 mg every 8 hr)

2. Nausea, vomiting, dizziness, headaches, hepatic toxicity 3. Diarrhea, rash, dizziness, headache, nausea, vomiting

Class IB 1. Dyspnea, respiratory depression, cardiac arrhythmias, hypotension 2. Palpitations, chest pain, nausea, vomiting, dizziness, tingling 3. PVCs, nausea, vomiting, dizziness


206


Page 206 6:24 PM 4/6/07 07White (F)-07

Antiarrhythmic Agents (Continued)


Availability

Strength (Dosage)

Side Effects

Class IC 1. flecainide (Tambocor) 2. propafenone (Rythmol)

1. Tablets 2. Tablets

1. 50 & 100 mg (50 mg every 12 hr) 2. 150, 225, 300 mg (150 mg every 8 hr)

1. Dizziness, dyspnea, headache, nausea 2. Nausea, vomiting, dizziness

1. 10 mg/mL (0.05 mg over 1 min then continuous infusion 0.05 mg/kg/min) 2. 20, 40, 80, and 120 mg (40–80 mg daily)

1. Confusion, bradycardia, chest pain, hypotension 2. Bradycardia, fatigue, depression, blurred vision 3. Fatigue, weakness, dizziness

207

Class II 1. esmolol (Brevibloc)

1. IV

2. metoprolol (Lopressor)

2. Tablets, IV

3. nadolol (Corgard)

3. Tablets

4. propranolol (Inderal)

4. Tablets, IV

3. 10, 20, 40, 60, 80 mg, 1 mg/mL Inj solution (40–320 mg/day over 3 to 4 doses, IV 1mg in 10 mL over 5 min) 4. 50 mg, IV solution 1 mg/mL (PO 50 mg 2 daily, IV 5 mg at 5 min intervals up to 15 mg)

4. Fatigue, GI upset, hypotension, dizziness


PHARM


Page 207 6:24 PM 4/6/07 07White (F)-07


Availability

Strength (Dosage)

Side Effects

Class II 5. Tablets, IV

5. 2 mg/mL (5 mg slow IV push over 5 min wait 10 min then give a second 5 mg dose over 5 min)

5. Bradycardia, hypotension, heart failure, SVT, VTach

1. amiodarone (Cordarone)

1. Tablets, IV

2. dofetilide (Tikosyn)

2. Capsules

3. ibutilide (Corvert)

3. IV

1. 200 mg, 50 mg/mL inj solution 1. Dizziness, fatigue, ARDS, pulmonary (400–600 mg PO daily over fibrosis, CHF symp1–2 doses, IV 150 mg over 10 toms, nausea, vomiting min then 360 mg over 6 hr, then 145 mg over 18 hr) 2. Headache, chest pain, 2. 125, 250, 500 mcg (125–500 dizziness, dyspnea, mcg 2 daily depending on creatinine clearance) nausea 3. 0.1 mg/mL in solution (2 mg 3. Polymorphic single infusion) ventricular tachycardia, nausea, headache

Class III


208

PHARM


5. atenolol (Tenormin) Copyright © 2008 by F. A. Davis.

Page 208 6:24 PM 4/6/07 07White (F)-07



Availability

Strength (Dosage)

Side Effects

Class III 4. sotalol (Betapace)

4. Tablets

4. 80, 160, and 240 mg (80 mg 2 daily can ↑ to 240–320 mg/day)

4. Dyspnea, bradycardia, fatigue, dizziness, nausea, vomiting

1. diltiazem (Cardizem)

1. Tablets, IV

1. 30, 60, 90, and 120 mg, 5mg/mL inj solution (PO 30–120 mg 3 or 4 daily, IV 0.25 mg/kg over 5 min)

1. AV block, dizziness, nausea, vomiting, headache

2. verapamil (Calan)

2. Tablets, IV

2. 40, 80, and 120 mg, IV 2.5 mg/mL inj solution (PO 80 mg 3 or 4 daily, IV 5–10 mg bolus)

2. Headache, dizziness, fatigue, nausea

209

Class IV

PHARM


Page 209 6:24 PM 4/6/07 07White (F)-07



Availability

Strength (Dosage)

Side Effects

dobutamine (Dobutrex) dopamine (Inotropin)

IV

Blood pressure fluctuation, headache, nausea, vomiting Hypertension, ↑ myocardial O2 demand, nausea, vomiting, headache, ischemia

epinephrine (Adrenalin) inamrinone (Inocor) isoproterenol (Isuprel)

IV

250 mg vials (2–20 mcg/ kg/min) 40 mg/mL vial (low dose 1–5 mcg/kg/min, moderate dose 5–10 mcg/kg/min, high dose 10–20 mcg/kg/min) 1:10000 and 1:1000 (1 mg or 10 mL 1:10000) 5mg/mL vial (0.75 mg/kg not to exceed 1mg/kg) 1:5000 ampules (2–10 mcg/min)

milrinone (Primacor)

IV

norepinephrine

IV

IV

IV IV

1 mg in 10, 20, or 50 mL (50 mcg/kg over 10 min initial then 0.5mcg/kg/min) 1mg/mL inj solution (0.5–1.0 mcg/min)

Ischemia, angina, tachycardia Nausea, vomiting, arrhythmias, headache, dizziness, dyspnea Nervousness, headache, dizziness, tachycardia, nausea, vomiting Cardiac arrhythmias, headache, hypokalemia, tremors Nervousness, headache, dizziness, tachycardia, nausea, vomiting (Text continued on following page)

210


Page 210 6:24 PM 4/6/07 07White (F)-07

Vasopressor and Inotropic Agents


Availability

phenylephrine (Neo-Synephrine) vasopressin (Pitressin)

Strength (Dosage)

Side Effects

IV

10 mg/mL (10 mcg/kg/min)

IV

20 units/mL (40 units IV)

Tachycardia, nervousness, dizziness, tremor, dyspnea Headache, nausea, vomiting, ischemia

211

Calcium Channel Blockers Generic Name (Trade Name)

Strength (Dosage)

Side Effects

amlodipine (Norvasc) bepridil (Vascor) diltiazem (Cardizem)

Availability Tablets

2.5 mg (5–10 mg once daily)

Tablets

felodipine (Plendil)

Tablets

200, 300 mg (200–300 mg once daily) 30, 60, 90, 120 mg, 5mg/mL inj solution (PO 30–120 mg 3 or 4 daily, IV 0.25 mg/kg over 5 min) 2.5 mg (2.5–5 mg once daily)

Headache, fatigue, nausea, edema Headache, palpitations, nausea, drowsiness, nervousness AV block, dizziness, nausea, vomiting, headache

Tablets, IV

Headache, palpitations, nausea, edema (Text continued on following page)

PHARM


Page 211 6:24 PM 4/6/07 07White (F)-07

Vasopressor and Inotropic Agents (Continued)

Generic Name (Trade Name) isradipine (DynaCirc) nicardipine (Cardene) nifedipine (Procardia) nisoldipine (Sular) verapamil (Isoptin)

Availability

Strength (Dosage)

Tablets

5 and 10 mg (5–10 mg once daily) 2.5 mg/mL inj solution (5 mg/hr IV infusion) 10 and 20 mg (10–30 mg 3 to 4 daily) 10, 20, 30 and 40 mg (20–40 mg once daily) 180 and 240 mg (240–480 mg once daily)

IV Tablets Tablets Tablets

Side Effects Headache, dizziness, fatigue Headache, hypotension, nausea Dizziness, flushing, headaches, weakness Edema, headache, dizziness 1AV block, bradycardia, chest pain, dizziness

Vasodilators Generic Name (Trade Name) nesiritide (Natrecor)

Availability IV

Strength (Dosage) 1.5 mg powder for reconstitution (2 mcg/kg/min bolus then 0.01 mg/kg/min infusion)

Side Effects Hypotension, ventricular tachycardia, headache, dizziness, nausea, vomiting (Text continued on following page)

212


Page 212 6:24 PM 4/6/07 07White (F)-07

Calcium Channel Blockers (Continued)


Strength (Dosage)

Side Effects

IV, tablets

Hypotension, headache, nausea, vomiting

sodium nitroprusside (Nitroprusside)

IV

5 mg/mL inj solution, 0.3, 0.4 and 0.6 mg sublingual tablets (IV 5 mcg/min, PO 0.3–0.6 every 5 min) 25 mg/mL (0.1 mcg/kg/min)

213

Availability

nitroglycerin

Hypotension, hypoxic pulmonary vasoconstriction, headache, nausea, vomiting

Anticoagulants Generic Name (Trade Name) enoxaparin (Lovenox) heparin sodium (Heparin) warfarin (Coumadin)

Availability IV IV IV, tablets

Strength (Dosage)

Side Effects

100 and 150 mg/mL inj solution (1 mg/ kg subcutaneously every 12 hr) 1000 Units/mL (60 Units/kg bolus then 12 units/kg/hour) Powder for reconstitution to 2mg/mL, 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (2.5–10 mg/day)

Hemorrhage, nausea Hemorrhage, hypersensitivity Hemorrhage, hypersensitivity

PHARM


Page 213 6:24 PM 4/6/07 07White (F)-07

Vasodilators (Continued)


Availability

abciximab (ReoPro)

IV

aspirin

Tablets

clopidogrel (Plavix)

Tablets

dipyridamole (Persantine) eptifibatide (Integrilin)

Tablets

ticlopidine (Ticlid) tirofiban (Aggrastat)

Tablets

IV

IV

Strength (Dosage) 2 mg/mL inj solution (0.25 mg/kg IV over 10 to 60 min then 0.125 mg/kg/min infusion for 12 hr) 162 and 325 mg (162–325 mg PO) 75 mg (75 mg once daily)

25, 50, and 75 mg (75–100 mg PO 4 daily) 0.75 mg/mL and 2 mg/mL inj solution vials (180 mcg/kg over 1 to 2 min, followed by 2 mcg/kg/min infusion) 250 mg (250 mg PO 2 daily) 12.5 mg/50 mL inj solution (0.4 mcg/kg/min over 30 min followed by 0.1 mcg/kg/min)

Side Effects Hemorrhage, thrombocytopenia, hypotension, bradycardia, nausea, vomiting Anorexia, nausea, epigastric pain, allergic reactions Pain, fatigue, edema, headache, dizziness, dyspnea Dizziness, abdominal pain, headache, rash Hemorrhage, allergic reactions

Diarrhea, nausea, dyspepsia, rash Edema, pelvic pain, bradycardia, dizziness

214


Page 214 6:24 PM 4/6/07 07White (F)-07

Antiplatelet Agents

215


Availability

Strength (Dosage)

alteplase (Activase)

IV

50 and 100 mg vials (15 mg IV bolus over 1–2 min then 50 mg over 30 min then 35 mg over 60 min)

Hemorrhage, allergic reactions

Side Effects

reteplase (Retavase)

IV

10.4 Unit powder for reconstitution (10 Units IV over 10 min, then repeat in 30 min)

Same as for alteplase

streptokinase

IV

250,000, 750,000, and 1,500,000 Unit inj solution vials (1,500,000 Units IV over 60 min)


tenecteplase (TNKase)

IV

50 mg powder for reconstitution in 10 mL sterile water (30–50 mg depending on pt weight [kg])


urokinase

IV

250,000 Unit powder for reconstitution in sterile water (6000 Units/min infused into blocked artery)


PHARM


Page 215 6:24 PM 4/6/07 07White (F)-07

Thrombolytic Agents

Trade Name (Generic Name)

Availability

Strength (Dosage)

Side Effects

adenosine (Adenocard)

IV

3mg/mL (6mg IV push)

Flushing, light headedness, headache, diaphoresis, palpitations

amiodarone (Cordarone)

IV

50 mg/mL inj solution (IV 150 mg over 10 min then 360 mg over 6 hr, then 145 mg over 18 hr)

Dizziness, fatigue, ARDS, pulmonary fibrosis, CHF symptoms, nausea, vomiting

aspirin

Tablets

162 and 325 mg (162–325 mg PO)

Anorexia, nausea, epigastric pain, allergic reactions

atenolol (Tenormin)

IV

2 mg/mL (5 mg slow IV push over 5 min wait 10 min then give 2nd 5-mg dose over 5 min)

Bradycardia, hypotension, heart failure, SVT, VTach

atropine sulfate (Atropine)

IV

0.4 and 1.0 mg/mL (0.5–1 mg IV every 5 min)

Myocardial ischemia, PVCs, worsening AV blocks

digoxin (Lanoxin)

IV

0.1 mg/mL (10–15 mcg/kg loading CHF symptoms, cardiac dose) arrhythmias, hypotension (Text continued on following page)

216


Page 216 6:24 PM 4/6/07 07White (F)-07

Advanced Cardiac Life Support (ACLS) Drugs

Trade Name (Generic Name) Availability

Strength (Dosage)

Side Effects

IV

5mg/mL inj solution (IV 0.25 mg/kg over 5 min)

AV block, dizziness, nausea, vomiting, headache

dobutamine (Dobutrex) dopamine (Intropin)

IV

250-mg vials (2–20 mcg/kg/min)

IV

epinephrine (Adrenalin) esmolol (Brevibloc)

IV

lidocaine (Xylocaine)

IV

40-mg/mL vial (low dose 1–5 mcg/kg/min, moderate dose 5–10 mcg/kg/min, high dose 10–20 mcg/kg/min) 1:10000 and 1:1000 (1 mg or 10 mL 1:10000) 10 mg/mL (0.05 mg over 1 min then continuous infusion 0.05 mg/kg/min) 4%, 10%, 20% (1 mg/kg)

Blood pressure fluctuation, headache, nausea, vomiting Hypertension, ↑ myocardial O2 demand, nausea, vomiting, headache, ischemia

metoprolol (Lopressor)

IV

217

diltiazem (Cardizem)

IV

IV solution 1 mg/mL ( IV 5 mg at 5 min intervals to 15 mg)

Ischemia, angina, tachycardia Confusion, bradycardia, chest pain, hypotension Dyspnea, respiratory depression, cardiac arrhythmias, hypotension Fatigue, GI upset, hypotension, dizziness (Continued text on following page)

PHARM


Page 217 6:24 PM 4/6/07 07White (F)-07

Advanced Cardiac Life Support (ACLS) Drugs (Continued)

Trade Name (Generic Name) Availability morphine sulfate IV

Strength (Dosage) 0.5 and 1.0 mg/mL (2–4 mg IV over 1–5 min) 5 mg/mL inj solution, 0.3, 0.4, and 0.6 mg sublingual tablets (IV 5 mcg/ min, PO 0.3–0.6 every 5 min) 1 mg/mL inj solution (40–320 mg/day over 3 to 4 doses, IV 1 mg in 10 mL over 5 min) 100 mg/mL (20 mg/min IV infusion)

nitroglycerin

IV, tablets

propranolol (Inderal)

IV

procainamide (Procanbid)

IV

sodium bicarbonate

IV

4% or 40 mg/mL solution (1 mEq/kg IV bolus)

vasopressin (Pitressin) verapamil (Calan)

IV

20 Units/mL (40 Units IV)

IV

IV 2.5 mg/mL inj solution (IV 5–10 mg bolus)

Side Effects Hypersensitivity, respiratory depression Hypotension, headache, nausea, vomiting Fatigue, weakness, dizziness Nausea, vomiting, dizziness, headaches, hepatic toxicity Metabolic acidosis, hypoxia, electrolyte imbalance, seizures Headache, nausea, vomiting, ischemia Hypotension, headache, dizziness, fatigue, nausea

218


Page 218 6:24 PM 4/6/07 07White (F)-07

Advanced Cardiac Life Support (ACLS) Drugs (Continued)

07White (F)-07

4/6/07

6:24 PM

Page 219


219 Starting an IV ■ Gather appropriate equipment ■ Exam gloves ■ Iodine and alcohol swabs ■ Rubber tourniquet ■ IV catheter ■ Tape/dressing ■ IV tubing and IV solution ■ Position the patient ■ Palpate potential sites ■ Apply the tourniquet ■ Prep the site ■ Aseptically prepare catheter and IV tubing/solution ■ Insert IV catheter ■ Observe for “flash” ■ Advance catheter ■ Apply pressure proximal to IV site ■ Attach IV tubing and IV solution ■ Remove tourniquet ■ Secure IV site with tape/dressing ■ Establish appropriate drip rate/monitoring

Dosage Calculations Ratio and Proportion Original Dose Desired Dose Amount XAmount Desired Dose XAmount Amount Original Dose

PHARM

07White (F)-07

4/6/07

6:24 PM


Page 220

PHARM

Example: You have a stock solution of 5 mg/mL. You need a 2.5 mg dose. How much do you draw up? Original Dose Desired Dose Amount XAmount 5 mg 2.5 mg mL XAmount 2.5 mg X 0.5 mL mL 5.0 mg

Percent Solutions The key to percent solutions is to convert them to mg/mL. One percent equals 1 gram of active drug in one hundred milliliters dilute or solution. Example: You have a stock solution of 0.5% and need a 2.5 mg dose. How much do you need? 5 gm 0.005 gm 5 mg 0.5% 100 mL mL mL Original Dose Desired Dose Amount XAmount 2.5 mg 5 mg XAmount mL 2.5 mg X 0.5 mL mL 5.0 mg

220

08White (F)-08

4/6/07

11:22 AM

Page 221


221 Frequently Used Phone Numbers Security ICU Emergency Room ER (Fast Track) CCU NICU PICU Advanced Care (ECG Telemetry) PFT LAB Surgery Short Stay Surgery Cardiology/Echocardiography X-Ray Radiology Pharmacy Laboratory Microbiology Pathology Physical Therapy Occupational Therapy Infection Control IV Therapy Medical Floor Oncology Floor Psych Floor Orthopedics Floor Pediatrics Floor Surgical Floor

TOOLS

08White (F)-08

4/6/07

11:22 AM


Page 222

TOOLS

Frequently Used Phone Numbers (Continued) Women’s/Post Partum Biomedical Department Information Technology Help Desk Admitting Central Cervices/Central Supply Chaplain Patient Ombudsman Social Work/Case Management Library Maintenance Employee Health Human Resources Other Other

Physician’s Contact Information Name Specialty Office/Cell Name Specialty Office/Cell Name Specialty Office/Cell

222

08White (F)-08

4/6/07

11:22 AM

Page 223


223 Physician’s Contact Information (Continued) Name Specialty Office/Cell Name Specialty Office/Cell Name Specialty Office/Cell Name Specialty Office/Cell Name Specialty Office/Cell Name Specialty Office/Cell Name Specialty Office/Cell

TOOLS

08White (F)-08

4/6/07

11:22 AM

Page 224


TOOLS

Physician’s Contact Information (Continued) Name Specialty Office/Cell

Physician Consultation Physician:

Office Phone:

Cell Phone:

Specialty: Patient Name Date/Time Patient Diagnosis Vital Signs

HR

Oxygenation

PaO2

RR

BP

PaO2/FIO2 Ventilation

VE

Temp

QS/QT FIO2/liter flow

VT

Rate

RSBI

VD/VT

Breath Sounds ABGs

pH

PaCO2

HCO3

PaO2

SaO2

Hb

Chest X-Ray Ventilator Settings

Mode

Rate/Hz

PIP / ▲ P

PEEP/MAP

PS

VT

FIO2

TI

TE

I:E

VE

Concerns Suggestions Order Changes

224

SpO2

TOOLS


Name Address Telephone/Fax Contact Person

Services Provided

225

Page 225 11:22 AM 4/6/07 08White (F)-08

Frequently Used Home Care Companies

Oxygen ■

Nebulizers ■ CPAP ■ Apnea Monitoring ■

Home Ventilators ■

Oxygen ■



Name Address Telephone/FAX Contact Person

Services Provided

TOOLS Name Address Telephone/Fax Contact Person

Services Provided

Oxygen ■



Oxygen ■



226


Page 226 11:22 AM 4/6/07 08White (F)-08

Frequently Used Home Care Companies (continued)


Services Provided


227

Services Provided

Oxygen ■

Nebulizers ■ CPAP ■

Apnea Monitoring ■ Home Ventilators ■

Oxygen ■



Name Address

08White (F)-08

Telephone/Fax Contact Person

Services Provided

TOOLS


Page 227 11:22 AM 4/6/07


TOOLS Name Address Telephone/Fax Contact Person

Services Provided

Oxygen ■



Oxygen ■



228


Page 228 11:22 AM 4/6/07 08White (F)-08



Services Provided

08White (F)-08

4/6/07

11:22 AM

Page 229


229 Home Care Referral Notes Patient Name Patient’s Date of Birth Patient’s Address Patient’s Telephone

- Home

- Cell

Patient’s SSN Ordering Physician Patient’s Diagnosis

HX of cor pulmonale, or CHF, or erythrocythemia Y ■ N ■

Room Air SpO2 Exercise Room Air SpO2 Nocturnal Room Air SpO2 Blood Gas Results

pH PaO2

PaCO2 SaO2

HCO3 FIO2/liter flow:

SpO2 with oxygen

% Device:

Oxygen referral?

Yes ■ No ■ Oxygen order: Yes ■ No ■ Medication: Frequency: Yes ■ No ■ PSG Sleep study date: PSG results: CPAP pressure: Bilevel Positive Airway Pressure: Ramp: Heated Humidity Ordered? Yes ■ No ■

Nebulizer referral? CPAP referral?

Liter Flow/FIO2:

TOOLS

08White (F)-08

11:22 AM

TOOLS

Page 230

ACLS NRP Misc. Misc.

PALS CPR Misc. Misc.

230


4/6/07

Schedule Planner/Organizer month_________

08White (F)-08

231

4/6/07

Page 231


11:22 AM

Schedule Planner/Organizer

ACLS NRP Misc. Misc.

PALS CPR Misc. Misc.

TOOLS

month _________

Event

Details

232

TOOLS Date/Time Copyright © 2008 by F. A. Davis.

Page 232 11:22 AM 4/6/07 08White (F)-08

Event Scheduler (Projects, Term Papers, Examinations, Seminars, Classes, etc.)

08White (F)-08

4/6/07

11:22 AM

Page 233


233 Frequently Used Equations Physiology

Oxygenation CvO2 SvO2 (1.34 Hb) (PvO2 0.003) CaO2 CvO2 O2ER CaO2 CcO2 CaO2 Qs/QT CcO2 CvO2 CaO2 SaO2 (Hb 1.34) (PaO2 0.003) DO2 QT (CaO2 10) VO2 QT (Ca-vO2 10) PaCO2 PAO2 FIO2 (PB 47 mmHg) 0.8 CcO2 1.0 (Hb 1.34) (PAO2 0.003)

Ventilation f RSBI VT VE VT f Anatomic Deadspace Estimation: VD 1 mL Body Weight(Lb) Bohr Equation (deadspace to tidal volume ratio): PaCO2 PECO2 VD/VT PaCO2 Alveolar Ventilation: VA (VD/VT VT)f

TOOLS

08White (F)-08

4/6/07

11:22 AM

Page 234


TOOLS

Corrected VT Static Compliance: CST Plateau Pressure PEEP Corrected VT Dynamic Compliance: CDYN Peak Pressure – PEEP

Hemodynamics

SV SVI BSA CO CI BSA

RVSWI SVI (PA – CVP) 0.013 gm/mL LVSWI SVI (MAP – PCWP) 0.013 gm/mL PA – PCWP PVR 80 CO

Blood Gas Formulas AG Na (CI HCO3)

Anion Gap:

Winter’s Formula: PaCO2 1.5(HCO3) 8(2) Delta Gap: Corrected HCO3 (HCO3 (AG – 12)) Metabolic Acidosis (Expected PaCO2): PaCO2 0.9(HCO3) 9

Nutritional weight in pounds 703 BMI (height in inches)2 Anion gap (Na K) (CI HCO3)

234

08White (F)-08

4/6/07

11:22 AM

Page 235


235 Equipment Calculations

Cylinder Duration 0.28[Pres(psi)] “E” Cylinder Time L/min 3.14[Pres(psi)] “H” Cylinder Time L/min

Liquid System Duration (in min) 0.8 [(Weight – Empty Weight) 343 L/Lb Liquid Oxygen] Liter Flow (L/min)

Pharmacology Original Dose Desired Dose Ratio and Proportions: Amount XAmount Percent Solution to mg/mL: 5 gm 0.005 gm 5 mg 0.5% 100 mL mL mL

TOOLS

08White (F)-08

4/6/07

11:22 AM


Page 236

TOOLS

Common Abbreviations ABG . . . . . . .Arterial Blood Gas ac . . . . . . . . . . . . . .Before Meals ACS . . . . . . . . .Acute Coronary Syndrome ADLs . . . . . .Activities of Daily . . . . . . . . . . . . . . . . . . . .Living AF . . . . . . . . .Atrial Fibrillation AFB . . . . . . .Acid Fast Bacillus ALS . . . . . . . . . . .Amyotrophic Lateral Sclerosis AMA . . . . . . . .Against Medical Advice AMI . . . . . . .Acute Myocardial Infarction ANT . . . . . . . . . . . . . .Anterior A-P . . . . . . . . . . . . . .Anterior Posterior ARDS . . . . . .Adult Respiratory Distress Syndrome ARF . . . . . . .Acute Respiratory Failure ASD . . . . . . . . . . .Atrial Septal Defect AV . . . . . . . . . .Atrioventricular BE . . . . . . . . . . . . .Base Excess BBB . . . . . . . . .Bundle Branch Block bid . . . . . . . . . . . . .Twice Daily BiPAP . . . . . . .Bi-Level Positive Airway Pressure BMR . . . . . . . .Basal Metabolic Rate BP . . . . . . . . . .Blood Pressure bpm . . . . . . .Beats Per Minute BS . . . . . . . . . .Breath Sounds BSA . . . . . .Body Surface Area

BUN . . . .Blood Urea Nitrogen c . . . . . . . . . . . . . . . . . . . .With CA . . . . . . . . . . . . . . . . .Cancer CABG . . . . . . .Coronary Artery Bypass Graft CAD . . . . . . . .Coronary Artery Disease CBC . . .Complete Blood Count CHF . . . . . . .Congestive Heart Failure CHO . . . . . . . . . .Carbohydrate CMV . . . . . . . . . . .Continuous Mechanical Ventilation CNS . . . . . . . .Central Nervous System CO . . . . . . . . . .Cardiac Output COPD . . . .Chronic Obstructive Pulmonary Disease CPR . . . . . . .Cardiopulmonary Resuscitation CPT . . . . .Chest Physiotherapy C&S . . .Culture and Sensitivity CSF . . . .Cerebral Spinal Fluid CT . . . . . . . . . . .Computerized Tomography CVA . . . . . . . . .Cardiovascular Accident CVP . . . . . . . . .Central Venous Pressure CW . . . . . . . . . . . . .Chest Wall CXR . . . . . . . . . . .Chest X-Ray DC . . . . . . . . . . . . .Discontinue DIC . . . . . . . . . . .Disseminated Intravascular Coagulation

236

08White (F)-08

4/6/07

11:22 AM

Page 237


237 DLCO . . .Single Breath Carbon Monoxide Diffusing Capacity DNR . . . . .Do Not Resuscitate DOA . . . . . . . .Dead on Arrival DOB . . . . . . . . . . .Date of Birth DOE . . . .Dyspnea on Exertion DTs . . . . . . .Delirium Tremens Dx . . . . . . . . . . . . . .Diagnosis ECF . . .Extended Care Facility ECG . . . . . .Electrocardiogram ECHO . . . . . . .Echocardiogram ECMO . . . . . . . .Extracorporeal Membrane Oxygenation EEG . . .Electroencephalogram EENT . .Eyes Ears Nose Throat EMG . . . . . .Electromyelogram EMS . . . . .Emergency Medical Service ENT . . . . . .Ear, Nose & Throat ER . . . . . . . .Emergency Room ESR . . . . . . . . . . . .Erythrocyte Sedimentation Rate ET . . . . . . . .Endotracheal Tube ETOH . . . . . . . . .Ethyl Alcohol FUO . . . . . .Fever of Unknown Origin Fx . . . . . . . . . . . . . . . .Fracture g, gm . . . . . . . . . . . . . . .Gram GFR . . . .Glomerular Filtration Rate GI . . . . . . . . . .Gastrointestinal gr . . . . . . . . . . . . . . . . . .Grain GSW . . . . . . .Gun Shot Wound gtt . . . . . . . . . . . . . . . . .Drops GU . . . . . . . . . . .Genitourinary GYN . . . . . . . . . . .Gynecology HAV . . . . . . . .Hepatitis A Virus Hb . . . . . . . . . . . .Hemoglobin

HBV . . . . . . . .Hepatitis B Virus Hct . . . . . . . . . . . . .Hematocrit HCV . . . . . . . .Hepatitis C Virus HEENT . .Head Eyes Ears Nose Throat HIV . . . . . . . .Human Immunodeficiency Virus HR . . . . . . . . . . . . . .Heart Rate hs . . . . . . . . . . .Hours of Sleep HTN . . . . . . . . . .Hypertension Hx . . . . . . . . . . . . . . . . .History I&O . . . . . . .Intake and Output IABP . . . . .Intra-aortic Balloon Pump ICP . . . . .Intracranial Pressure ICU . . . . . .Intensive Care Unit IDDM . . . . .Insulin Dependent Diabetes Mellitus IM . . . . . . . . . . .Intramuscular IV . . . . . . . . . . . . .Intravenous JVD . . . . . . . . .Jugular Venous Distention kg . . . . . . . . . . . . . . .Kilogram L . . . . . . . . . . . . . .Liter or Left LAD . . . .Left Anterior Descending (coronary artery) LAT . . . . . . . . . . . . . . . .Lateral LLL . . . . . . . . .Left Lower Lobe LOC . . . . . . . . . . .Level/Loss of Consciousness LP . . . . . . . . .Lumbar Puncture LUL . . . . . . . .Left Upper Lobe LV . . . . . . . . . . . .Left Ventricle LVAD . . . . . . . .Left Ventricular Assist Device MAP . . . . . . . . . .Mean Arterial Pressure or Mean Airway Pressure

TOOLS

08White (F)-08

4/6/07

11:22 AM


Page 238

TOOLS

mcg . . . . . . . . . . . .Microgram MD . . . . .Muscular Dystrophy MDI . . . . . . . . . .Metered Dose Inhaler mEq . . . . . . . . .Milliequivalent mg . . . . . . . . . . . . . .Milligram MI . . . . .Myocardial Infarction mL . . . . . . . . . . . . . . .Milliliter mm . . . . . . . . . . . . .Millimeter mmHg . . . . . . . .Millimeters of Mercury MMR . . . . . .Measles-MumpsRubella MRI . . . . .Magnetic Resonance Imaging MRSA . . .Methicillin-Resistant Staphylococcus aureus NEB . . . . . . . . . . .Nebulized or Nebulizer NG . . . . . . . . . . . .Nasogastric NGT . . . . . . .Nasogastric tube NICU . . . . .Neonatal Intensive Care Unit NKA . . . . .No Known Allergies NKDA . . . . . . .No Known Drug Allergies noc . . . . . . . . . . . . . .Nocturnal NPO . . . . . .Nothing by Mouth (per os) NRB . . . . . . . .Non-Rebreather OB . . . . . . . . . . . . . .Obstetrics OD . . . . . . . . . . . . . .Overdose OR . . . . . . . . .Operating Room OT . . . . . . . . . . . .Occupational Therapy OTC . . . . . . .Over-the-Counter P . . . . . . . . . . . . . . . . .Pressure p . . . . . . . . . . . . . . . . . . . .After

PA..................Posterior-Anterior PAC..................Premature Atrial Complex PAR...................Post Anesthesia Recovery PAT ................Paroxysmal Atrial Tachycardia PDA......................Patent Ductus Arteriosus PE .............Pulmonary Embolus PEA .............Pulseless Electrical Activity PEEP....Positive End Expiratory Pressure PFT............Pulmonary Function Test PICC .........Peripherally Inserted Central Catheter PIH ..............Pregnancy Induced Hypertension PMH .........Past Medical History PMI.................Point of Maximal Impulse PND .......Paroxysmal Nocturnal Dyspnea PO ................By Mouth (per os) prn ............................As Needed PSVT.....Paroxysmal Supraventricular Tachycardia PT .................Prothrombin Time PTT........Partial Thromboplastin Time PVC.........Premature Ventricular Contraction q.........................................Every qd...............................Every Day qh .............................Every Hour q2 ........................Every 2 Hours q3 ........................Every 3 Hours

238

08White (F)-08

4/6/07

11:22 AM

Page 239


239 q4 ........................Every 4 Hours q6 ........................Every 6 Hours q8 ........................Every 8 Hours q12 ....................Every 12 Hours qid...................Four Times Daily R .........................................Right RA..........................Right Atrium RLL ................Right Lower Lobe RML .............Right Middle Lobe R/O...............................Rule Out ROM ...............Range of Motion RUL ...............Right Upper Lobe Rx............................Prescription s .....................................Without SA ...............................Sinoatrial SIDS .........Sudden Infant Death Syndrome SNF ...................Skilled Nursing Facility SOB...................Short of Breath Staph................Staphylococcus STAT.......................Immediately Strep ...................Streptococcus Subq ...................Subcutaneous SV.......................Stroke Volume SVR...............Systemic Vascular Resistance T.............................Temperature T&A ..............Tonsillectomy and Adenoidectomy TB ..........................Tuberculosis TEE .................Transesophageal Echocardiogram

TIA ...............Transient Ischemic Attack tid ..................Three times daily TKO .....................To Keep Open TLC ............Total Lung Capacity TPN...................Total Parenteral Nutrition TPR . . . . .Temperature, Pulse, Respirations Tx . . . . . . . . . . . . . . .Treatment UA . . . . . . . . . . . . . .Urinalysis URI . . . . . . .Upper Respiratory Infection UTI . . . . . . . . . . . .Urinary Tract Infection UV . . . . . . . . . . . . . .Ultraviolet VC . . . . . . . . . . .Vital Capacity VF . . . . . . . . . . . . . .Ventricular Fibrillation V/Q Scan . . . . . . . .Ventilation/ Perfusion Scan VRE . . . . . . . . . . .VancomycinResistant Enterococcus WA . . . . . . . . . . .While Awake WBC . . . . . . .White Blood Cell Count WNL . . . . . . . . .Within Normal Limits w/o . . . . . . . . . . . . . . .Without wt . . . . . . . . . . . . . . . . .Weight yo . . . . . . . . . . . . . . . .Year Old yr . . . . . . . . . . . . . . . . . . . .Year

TOOLS

09White (F)-Index

4/6/07


11:20 AM

Page 240

TOOLS

Index description of, 22, 64 medications for, 201–202 Asystole, 53 Atelectasis, 23, 45 Atrial fibrillation, 48 Atrioventricular block, 51–52 Auscultation chest, 18–19 heart, 25–26 Automated external defibrillator, 158 Auto-PEEP, 136–137

A Abbreviations, 236–239 Adolescent, 3 Adults, 4, 65–67 Advanced cardiac life support algorithms for, 160–167 drugs used in, 216–218 pediatric, 187–190 Aerosol tent, 73 Aerosol therapy, 71–76, 181 African Americans, 5 Age-specific considerations, 2–4 Airborne precautions, 1 Air-trapping, 136–137 Airway management advanced airways, 108–109 intubation, 109–110 manual resuscitators, 107 in newborn, 175–176 positional maneuvers, 106 Airway resistance, 138–139 Alveolar ventilation, 20, 233 Anatomic deadspace, 20, 233 Anion gap, 113, 234 Anterior-posterior chest x-ray, 42 Antiarrhythmic drugs, 205–209 Anticholinergic agents, 196–197 Anticoagulants, 213 Antimicrobial agents, 204 Antiplatelet agents, 214 Apgar score, 168–169 Arab Americans, 5 Arterial blood gases assessment of, 37–41, 113 formulas, 234 in newborn, 168 Arterial pressure monitoring, 53 Artificial airway care of, 110–111 management of. See Airway management Asbestosis, 64 Assessment, 30–33 Asthma

B Bag/mask ventilation, 175 Ballard gestational age assessment, 170–171 Basic life support, 150–158 Bilevel positive airway pressure, 79 Biot’s respiration, 16 Blood gases. See Arterial blood gases Blood pressure, 13–14, 24, 112 Body fat, 28 Body mass index, 28, 234 Bohr equation, 233 Bosnian Americans, 6 Bradycardia advanced cardiac life support, 162 algorithms for, 162, 188 sinus, 48 Bronchial hygiene, 81–90 Bronchial sounds, 18 Bronchitis, 22, 64 Bronchodilators, 182, 194–198 Bronchoscopy, fiberoptic, 91–94 Bronchovesicular sounds, 18 Bruits, 27 C Calcium channel blockers, 211–212 Capillary refill, 24 Capnography, 96–97 Cardiac auscultation, 25–26 Cardiac enzymes, 27 Cardiac glycosides, 205

240

09White (F)-Index

4/6/07

11:20 AM

Page 241


241 Cardiac index, 57 Cardiac palpation, 25 Cardiopulmonary resuscitation in adults, 150 in child, 152–153 in infant, 155–156 in newborn, 177 Central venous pressure lines, 54 Chest auscultation, 18–19 inspection of, 15 percussion of, 18 symmetry assessments, 17 Chest discomfort, 166–167 Chest physiotherapy and postural drainage, 83 Chest x-rays, 41–45 Cheyne-Stokes respiration, 16 Child, 3, 152–154 Combitude airway, 108 Complete blood count, 34 Compliance in scalar waveforms, 142, 144 in volume loops, 141, 143 Congestive heart failure, 45 Consultation, 224 Contact precautions, 1 Continuous positive airway pressure, 79 Conversions, 8–9 Corticosteroids, 199–201 Cough, 20 Crackles, 18 Critically ill patients cardiovascular assessment, 103 fluid and electrolytes, 104 monitoring of, 112–114 neurological assessment, 104 oxygenation assessment, 102–103 physical findings, 101–102 ventilatory assessment, 102 ventilatory failure, 105 vital signs, 101 Cultural diversity, 5–7 Cylinder duration, 235 Cystic fibrosis, 23 Cytology, 36–37

D Double lumen endotracheal tubes, 109 Droplet precautions, 1 Dual-controlled ventilation, 118, 120 Dynamic compliance, 234 E Elderly, 4 Electrocardiogram, 46–53 Emphysema, 22, 64 Endotracheal tubes, 109 Equations, 233–234 Eupnea, 16 Event scheduler, 232 Exercise testing, 98–100 Expiratory reserve volume, 58 Extubation, 149 F Fiberoptic bronchoscopy, 91–94 Flow loop, 127, 136 Flow scalar waveform, 123 Forced expired volume in 1 second, 59 Forced vital capacity, 59 Foreign body airway obstruction in adults, 151 in child, 154 in infant, 157 Fraction of inspired oxygen, 121 Frequently used phone numbers, 221–222 Functional residual capacity, 59 G Gestational age assessment, 170–171 Glasgow Coma Score, 104 H Head assessment, 15 Heart rate, 13–14, 24, 112 Heart sounds, 25–26 Heat and moisture exchanger, 74 Hematocrit, 34 Hematology, 34 Hemodynamics, 53–58, 234 Hemoglobin, 34

TOOLS

09White (F)-Index

4/6/07


Histology, 36–37 Home care frequently used companies, 225–228 referral notes, 229 Humidifiers, 73–74 Humidity therapy, 71–76 Hyperinflation therapy, 76–81, 185 I Incentive spirometry, 77 Indwelling arterial lines, 53 Infants, 2, 155–157 Inhaled antimicrobial agents, 204 Inotropic agents, 210–211 Inspiratory capacity, 59 Inspiratory reserve volume, 58 Intermittent positive pressure breathing, 79 Interview, 11–13 Intrapulmonary percussive ventilation, 84 Intravenous line, 219–220 Intubation, 109–110, 176 Ischemia, 166–167 Isolation precautions, 1 K Kussmaul’s respiration, 16 L Laryngeal mask airway, 108 Lateral chest x-ray, 43 Left ventricular stroke work index, 57 Length conversions, 8–9 Life support advanced cardiac. See Advanced cardiac life support basic, 150–158 Loops, 126–127 Lung drainage, 85–88 M Mandatory breath, 130, 134 Manual resuscitators, 107 Mean cell hemoglobin, 34 Mean cell hemoglobin concentration, 34

11:20 AM

Page 242

TOOLS

Mean cell volume, 34 Mechanical ventilation discontinuance of, 147–149 dual-controlled ventilation, 118, 120 fraction of inspired oxygen, 121 indications for, 114–115 inspiratory flow pattern, 122 loops, 126–127 minute ventilation, 121 modes of, 115–118, 149 pressure-controlled ventilation, 117, 120, 122, 132–135 return to, 148 tidal volume, 121 ventilator. See Ventilator volume-controlled ventilation, 116, 119, 122, 128–131 waveforms, 122–127 weaning, 147 Metabolic acidosis, 39–40, 234 Metabolic alkalosis, 39–41 Metered dose inhalers, 74 Mexican Americans, 7 Microbiology, 36 Minute ventilation, 121 Minute volume, 20 Mucolytic therapy, 183 Mucous agents, 202–203 Murmurs, 27 N Nasal cannula, 67, 180 Nasal inhaled corticosteroids, 200–201 Native Americans, 6 Nebulizers, 73–74 Neck assessment, 15 Neurological assessment, 27–28 Newborn acute care of, 174–193 airway management in, 175–176 Apgar score, 168–169 assessment of, 168–174 bland aerosol algorithm, 181 bronchodilators, 182 cardiopulmonary resuscitation algorithm, 177 gestational age, 170–171

242

09White (F)-Index

4/6/07

11:20 AM

Page 243


243 HFOV ventilator management algorithm, 179 hyperinflation therapy in, 185 mucolytic therapy, 183 oxygen therapy in, 180 physical maturity, 172–173 respiratory care, 180 respiratory status, 174 secretion mobilization in, 186 vasoconstrictors, 184 ventilator management, 178 vital signs, 168 Non-rebreathing mask, 67, 180 Nonsteroidal anti-inflammatory drugs, 201–202 Nutritional assessment, 28–29 O Organizer, 230–231 Overdistention, 145 Oximetry, 100 Oxygen therapy description of, 65–70 in newborn, 180 Oxygenation, 21, 233 P Partial rebreathing mask, 67 Patient interview, 11–13 Percent solutions, 220 Percussion, 18 Pharmacology equations, 235 Phone numbers, 221–222 Physician consultation with, 224 contact information for, 222–224 Platelets, 34 Pleural effusion, 45 Pneumonia, 23 Pneumothorax, 45 Point of maximal impulse, 25 Portable sleep monitoring, 97–98 Positive expiratory pressure, 78, 83, 131, 135 Posterior-anterior chest x-ray, 42 Postural drainage, 85–88

Premature ventricular contraction, 49 Pressure conversions, 9–10 Pressure loop, 126 Pressure scalar waveform, 124 Pressure-controlled ventilation, 117, 120, 122, 132–135 Pulmonary artery catheter, 55 Pulmonary artery pressures, 57 Pulmonary edema, 23, 45 Pulmonary embolus, 23 Pulmonary function testing, 58–64 Pulmonary inhaled corticosteroids, 199–200 Pulmonary secretions, 35 Pulmonary vascular resistance, 57 Pulseless arrest, 160–161, 189 R Red blood cells, 34 Residual volume, 58 Respiratory acidosis, 40 Respiratory alkalosis, 40 Respiratory failure, 105 Respiratory rate, 13–14, 112 Resuscitators, 107 Retinol-binding protein, 29 Rhonchi, 18 Right ventricular stroke work index, 57 Rub, 18 Russian Americans, 7 S Sarcoidosis, 64 Scalar waveforms airway resistance in, 139 compliance in, 142, 144 description of, 122–123, 137 Schedule planner, 230–231 Serum albumin, 29 Simple oxygen mask, 67, 180 Sinus bradycardia, 48 Skin testing, 37 Sleep monitoring, portable, 97–98 Spirometry, 59–60, 77 SpO2, 13–14

TOOLS

09White (F)-Index

4/6/07

11:20 AM


Spontaneous breath flow triggered, 129, 133 pressure triggered, 128–129, 132 Spontaneous breathing trial, 148 Sputum, 20 Static compliance, 234 Stroke volume index, 57 Suctioning, of airway description of, 111–112 in newborn, 175 Surfactant agents, 203 Swan-Ganz catheter, 55 Sympathomimetic agents, 194–196 Systemic vascular resistance, 57 T Tachycardia with adequate perfusion, 190 advanced cardiac life support for, 164–165 algorithms for, 164–165, 192 with poor perfusion, 192–193 ventricular, 50 TB testing, 37 Temperature, 13–14, 112 Temperature conversions, 8–9 Thrombolytic agents, 215 Tidal volume, 20, 58, 121 Toddlers, 2 Total lung capacity, 59 Tracheostomy care, 90–91 Trigger asynchrony, 146 U Urea nitrogen, 29 Urine output, 113 V Vasoconstrictors, 184 Vasodilators, 212–213 Vasopressors, 210–211

Page 244

TOOLS

Ventilation assessment of, 20 bag/mask, 175 equations, 233–234 mechanical. See Mechanical ventilation Ventilator mandatory breath, 130, 134 in newborns, 178 normal graphics for, 128–135 settings for, 118 spontaneous breath, 128–129, 132 waveforms for, 122–127 Ventilatory failure, 105, 115 Ventilatory patterns, 16 Ventricular fibrillation, 50 Ventricular tachycardia, 50 Venturi mask, 67 Vesicular sounds, 18 Vital capacity, 59 Vital signs assessment of, 13–14 in critically ill patients, 101 in newborn, 168 Volume loops airway resistance in, 140 compliance in, 141, 143 description of, 126–127 Volume scalar waveform, 125 Volume-controlled ventilation, 116, 119, 122, 128–131 W Weaning, 147 Weight conversions, 8–9 Wheezes, 18 Winter’s formula, 234 X Xanthine, 198

244

Respiratory Notes: Respiratory Therapist's Pocket Guide (Davis's Notes)

Neuro Notes: Clinical Pocket Guide

Respiratory System

Respiratory System

Mobilization Notes: A Rehabilitation Specialist's Pocket Guide (Davis's Notes)

IV Med Notes: Nurse's Clinical Pocket Guide (Davis Notes)

Provider's Coding Notes: Billiing and Coding Pocket Guide (Davis's Notes)

Screening Notes: Rehabilitation Specialist's Pocket Guide (Davis Notes S.)

Respiratory Critical Care

Pulmonary Respiratory Therapy Secrets

Immunopharmacology of Respiratory System

Critical Care Notes: Clinical Pocket Guide

Nunn's Applied Respiratory Physiology

Neonatal Respiratory Care Handbook

LPN Notes: Nurse's Clinical Pocket Guide

Derm notes Dermatology Clinical Pocket Guide

Critical Care Notes: Clinical Pocket Guide

MedSurg Notes: Nurse's Clinical Pocket Guide

Pediatric Respiratory Medicine, Second Edition (Taussing, Pediatric Respiratory Medicine)

Respiratory Physiology: The Essentials

Clinical Respiratory Medicine

Severe Acute Respiratory Syndrome

Neonatal Respiratory Disorders

Equine Respiratory Diseases

Respiratory Disorders For Lawyers

Pulmonary Respiratory Therapy Secrets

Respiratory Physiology: The Essentials

Respiratory Notes: Respiratory Therapist's Pocket Guide (Davis's Notes)

Neuro Notes: Clinical Pocket Guide

Respiratory System

Respiratory System

Mobilization Notes: A Rehabilitation Specialist's Pocket Guide (Davis's Notes)

IV Med Notes: Nurse's Clinical Pocket Guide (Davis Notes)

Provider's Coding Notes: Billiing and Coding Pocket Guide (Davis's Notes)

Screening Notes: Rehabilitation Specialist's Pocket Guide (Davis Notes S.)

Respiratory Critical Care

Pulmonary Respiratory Therapy Secrets

Immunopharmacology of Respiratory System

Critical Care Notes: Clinical Pocket Guide

Nunn's Applied Respiratory Physiology

Neonatal Respiratory Care Handbook

LPN Notes: Nurse's Clinical Pocket Guide

Derm notes Dermatology Clinical Pocket Guide

Critical Care Notes: Clinical Pocket Guide

MedSurg Notes: Nurse's Clinical Pocket Guide

Pediatric Respiratory Medicine, Second Edition (Taussing, Pediatric Respiratory Medicine)

Respiratory Physiology: The Essentials

Clinical Respiratory Medicine

Severe Acute Respiratory Syndrome

Neonatal Respiratory Disorders

Equine Respiratory Diseases

Respiratory Disorders For Lawyers

Pulmonary Respiratory Therapy Secrets

Respiratory Physiology: The Essentials

Recommend Documents